HTG Molecular Diagnostics (HTGMQ) 10-Q 12 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 06, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Trading Symbol	HTGM
Entity Registrant Name	HTG Molecular Diagnostics, Inc
Entity Central Index Key	1,169,987
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		6,839,864

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 2,598,143	$ 3,613,392
Short-term investments available-for-sale, at fair value	28,711,759
Accounts receivable, net	696,827	801,125
Inventory, net of allowance of $328,022 at September 30, 2015 and $54,269 at December 31, 2014	2,266,182	1,685,814
Prepaid insurance	393,127	20,905
Prepaid expenses and other	223,472	91,130
Total current assets	34,889,510	6,212,366
Long-term investments available-for-sale, at fair value	7,766,952
Deferred financing and offering costs	59,582	1,369,281
Property and equipment:
Office equipment	442,490	414,424
Leasehold improvements	252,750	234,602
Laboratory and manufacturing equipment	3,127,484	2,003,693
Field equipment	180,355	286,044
Software	140,248	140,248
Construction in progress	49,953	6,125
Total property and equipment	4,193,280	3,085,136
Less: accumulated depreciation and amortization	(2,365,135)	(1,938,537)
Property and equipment, net	1,828,145	1,146,599
Total assets	44,544,189	8,728,246
Current liabilities:
Accounts payable	966,853	948,429
Accrued liabilities	1,407,998	1,499,750
Deferred revenue	32,716	41,248
NuvoGen obligation	362,500
Term loan	2,017,712	813,715
Total current liabilities	4,787,779	3,303,142
Redeemable convertible preferred stock warrant liability		730,543
Term loan payable - non-current, net of discount	8,738,683	9,705,655
NuvoGen obligation - non-current, net of discount	8,544,591	8,677,859
Other	36,447	58,380
Total liabilities	$ 22,107,500	22,475,579
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock		$ 55,922,593
Commitments and Contingencies
Stockholders’ equity (deficit):
Preferred stock, $0.001 par value; 10,000,000 and 0 authorized at September 30, 2015 and December 31, 2014, respectively; no shares issued and outstanding at either date.
Common stock, $0.001 par value; 200,000,000 and 600,000,000 shares authorized at September 30, 2015 and December 31, 2014, respectively; 6,841,260 and 6,839,864 shares issued and outstanding, respectively, at September 30, 2015, 334,003 and 332,607 shares issued and outstanding, respectively, at December 31, 2014	$ 6,840	$ 333
Additional paid-in-capital (distributions in excess of capital)	106,366,937	(1,426,556)
Treasury stock – 1,396 shares, at cost	(75,000)	(75,000)
Accumulated other comprehensive income	4,754
Accumulated deficit	(83,866,842)	(68,168,703)
Total stockholders' equity (deficit)	22,436,689	(69,669,926)
Total liabilities and stockholders' equity (deficit)	$ 44,544,189	8,728,246
Series A Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock		1,402,687
Stockholders’ equity (deficit):
Total stockholders' equity (deficit)		1,402,687
Series B Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock		2,099,310
Stockholders’ equity (deficit):
Total stockholders' equity (deficit)		2,099,310
Series C-1 Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock		4,567,525
Stockholders’ equity (deficit):
Total stockholders' equity (deficit)		4,567,525
Series C-2 Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock		2,223,506
Stockholders’ equity (deficit):
Total stockholders' equity (deficit)		2,223,506
Series D Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock		37,174,666
Stockholders’ equity (deficit):
Total stockholders' equity (deficit)		37,174,666
Series E Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock:
Total Redeemable Convertible Preferred Stock		8,454,899
Stockholders’ equity (deficit):
Total stockholders' equity (deficit)		$ 8,454,899

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Inventory net allowance	$ 328,022	$ 54,269
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	0
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	600,000,000
Common stock, shares issued	6,841,260	334,003
Common stock, shares outstanding	6,839,864	332,607
Treasury stock, shares	1,396	1,396
Series A Redeemable Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation value	$ 0	$ 1,406,369
Preferred stock, shares authorized	0	1,292,084
Preferred stock, shares issued	0	1,292,084
Preferred stock, shares outstanding	0	1,292,084
Preferred stock, par value	$ 0.001
Series B Redeemable Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation value	$ 0	$ 2,104,811
Preferred stock, shares authorized	0	11,919,624
Preferred stock, shares issued	0	6,789,712
Preferred stock, shares outstanding	0	6,789,712
Preferred stock, par value	$ 0.001
Series C-1 Redeemable Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation value	$ 0	$ 4,581,944
Preferred stock, shares authorized	0	17,530,800
Preferred stock, shares issued	0	13,242,612
Preferred stock, shares outstanding	0	13,242,612
Series C-2 Redeemable Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation value	$ 0	$ 2,244,343
Preferred stock, shares authorized	0	19,262,522
Preferred stock, shares issued	0	9,948,331
Preferred stock, shares outstanding	0	9,948,331
Series D Redeemable Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation value	$ 0	$ 68,001,923
Preferred stock, shares authorized	0	237,031,908
Preferred stock, shares issued	0	139,529,173
Preferred stock, shares outstanding	0	139,529,173
Preferred stock, par value	$ 0.001
Preferred stock, shares issued	723,050
Series E Redeemable Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation value	$ 0	$ 20,839,001
Preferred stock, shares authorized	0	185,046,445
Preferred stock, shares issued	0	45,938,041
Preferred stock, shares outstanding	0	45,938,041
Preferred stock, par value	$ 0.001

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue:
Product	$ 973,956	$ 532,240	$ 2,349,740	$ 977,386
Service	37,000	107,183	150,292	396,840
Other		230,822	325,789	656,917
Total revenue	1,010,956	870,245	2,825,821	2,031,143
Cost of revenue	809,015	747,342	2,538,590	2,005,276
Gross margin	201,941	122,903	287,231	25,867
Operating expenses:
Selling, general and administrative	3,717,402	2,610,354	10,883,161	7,116,544
Research and development	1,309,573	649,949	2,951,009	2,372,972
Total operating expenses	5,026,975	3,260,303	13,834,170	9,489,516
Operating loss	(4,825,034)	(3,137,400)	(13,546,939)	(9,463,649)
Other income (expense):
Loss from change in stock warrant valuation	0	0	(239,683)	(56,323)
Interest expense	(378,656)	(161,069)	(1,334,103)	(292,018)
Interest income	37,788		48,930
Loss on settlement of convertible debt			(705,217)
Other	8,239	(8,860)	78,873	(7,756)
Total other income (expense)	(332,629)	(169,929)	(2,151,200)	(356,097)
Net loss before income taxes	(5,157,663)	(3,307,329)	(15,698,139)	(9,819,746)
Net loss	(5,157,663)	(3,307,329)	(15,698,139)	(9,819,746)
Accretion of stock issuance costs	0	(19,488)	(35,046)	(71,175)
Accretion of Series D and E redeemable convertible preferred stock dividends		(837,225)	(1,165,932)	(2,405,987)
Net loss attributable to common stockholders	$ (5,157,663)	$ (4,258,935)	$ (17,026,733)	$ (12,548,801)
Net loss per share attributable to common stockholders, basic and diluted	$ (0.76)	$ (44.14)	$ (4.56)	$ (130.11)
Shares used in computing net loss per share attributable to common stockholders, basic and diluted	6,829,687	96,486	3,735,852	96,446
Series E Warrants
Other income (expense):
Accretion of Series E warrant discount	$ 0	$ (94,893)	$ (127,616)	$ (251,893)

Condensed Statements of Compreh

Condensed Statements of Comprehensive Income - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (5,157,663)	$ (3,307,329)	$ (15,698,139)	$ (9,819,746)
Other comprehensive income, net of tax effect:
Unrealized gain on short and long-term investments	12,993		4,754
Comprehensive loss	(5,144,670)	(3,307,329)	(15,693,385)	(9,819,746)
Less: Accretion of stock issuance costs		(19,488)	(35,046)	(71,175)
Less: Accretion of Series E warrant discount		(94,893)	(127,616)	(251,893)
Less: Accretion of Series D and E redeemable convertible preferred stock dividends		(837,225)	(1,165,932)	(2,405,987)
Comprehensive loss attributable to common stockholders	$ (5,144,670)	$ (4,258,935)	$ (17,021,979)	$ (12,548,801)

Condensed Statements of Redeema

Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders Equity (Deficit) - 9 months ended Sep. 30, 2015 - USD ($)	Total	Common Stock	Additional Paid-In-Capital (Distributions in Excess of Capital)	Treasury Stock	Accumulated Other Comprehensive Income	Accumulated Deficit	Series A Redeemable Convertible Preferred Stock	Series B Redeemable Convertible Preferred Stock	Series C-1 Redeemable Convertible Preferred Stock	Series C-2 Redeemable Convertible Preferred Stock	Series D Redeemable Convertible Preferred Stock	Series E Redeemable Convertible Preferred Stock
Balance at Dec. 31, 2014	$ (69,669,926)	$ 333	$ (1,426,556)	$ (75,000)		$ (68,168,703)	$ 1,402,687	$ 2,099,310	$ 4,567,525	$ 2,223,506	$ 37,174,666	$ 8,454,899
Balance, Redeemable convertible preferred stock shares at Dec. 31, 2014							1,292,084	6,789,712	13,242,612	9,948,331	139,529,173	45,938,041
Exercise of Series D and Series E warrants											$ 93,550	$ 11,312
Exercise of Series D and Series E warrants, shares											723,505	51,681
Exercise of stock options	34,048	$ 14	34,034
Exercise of stock options, shares		13,766
Share-based compensation expense	223,787		223,787
Accretion of redeemable convertible preferred stock issuance costs	(35,046)		(35,046)				$ 320	$ 839	$ 1,538	$ 2,113	$ 18,109	$ 12,127
Accretion of Series E warrant discount	(127,616)		(127,616)									127,616
Accretion of Series D and E redeemable convertible preferred stock dividend	(1,165,932)		(1,165,932)								876,955	288,977
Settlement of outstanding principal and accrued interest on convertible notes by issuance of common stock	4,544,384	$ 324	4,544,060
Settlement of outstanding principal and accrued interest on convertible notes by issuance of common stock, shares		324,591
Conversion of warrants from warrants for preferred stock to warrants for common stock	1,616,140		1,616,140
Conversion of preferred stock into common stock at initial public offering	57,356,049	$ 2,509	57,353,540				$ (1,403,007)	$ (2,100,149)	$ (4,569,063)	$ (2,225,619)	$ (38,163,280)	$ (8,894,931)
Conversion of preferred stock into common stock at initial public offering, shares		2,508,824					(1,292,084)	(6,789,712)	(13,242,612)	(9,948,331)	(140,252,678)	(45,989,722)
Issuance of common stock from initial public offering	45,354,186	$ 3,660	45,350,526
Issuance of common stock from initial public offering, shares		3,660,076
Net loss	(15,698,139)					(15,698,139)
Balance at Sep. 30, 2015	22,436,689	$ 6,840	$ 106,366,937	$ (75,000)	$ 4,754	$ (83,866,842)
Balance, shares at Dec. 31, 2014		332,607
Other comprehensive income	$ 4,754				$ 4,754
Balance, shares at Sep. 30, 2015		6,827,414

Condensed Statements of Redeem7

Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders Equity (Deficit) (Parenthetical) $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)
Statement Of Stockholders Equity [Abstract]
Initial public offering, issuance cost	$ 5.9

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating activities
Net loss	$ (15,698,139)	$ (9,819,746)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	473,799	365,100
Accretion of discount on NuvoGen obligation	229,232	141,551
Bad debt expense (recovery), net	44,854	117,467
Provision for excess inventory	273,752
Amortization of deferred financing costs	37,461	2,700
Amortization of discount on term loan	120,627	16,125
Amortization of final payment premium on term loan	116,398
Loss on settlement of convertible notes	705,217
Amortization of discount on convertible notes	90,222
Share-based compensation expense	223,787	119,506
Change in redeemable convertible preferred stock warrant liability	239,683	56,323
Loss on disposal of assets	67,780	35,960
Changes in operating assets and liabilities:
Accounts receivable	59,444	(353,117)
Inventory	(854,120)	(547,457)
Prepaid expenses and other	(505,918)	1,123
Accounts payable	(254,423)	(347,323)
Accrued liabilities	(47,367)	60,925
Deferred revenue	(8,532)	(64,548)
Other long term liabilities		(7,617)
Net cash used in operating activities	(14,686,243)	(10,223,028)
Investing activities
Purchase of property and equipment	(950,278)	(605,931)
Purchase of available-for-sale securities	(36,473,957)
Net cash used in investing activities	(37,424,235)	(605,931)
Financing activities
Proceeds from exercise of stock options	34,048	21,305
Draws on line of credit		750,000
Payments on line of credit		(750,000)
Payments on NuvoGen obligation	0	(1,206,250)
Proceeds from exercise of E warrants	8,948
Deferred offering costs	(1,002,930)	(193,280)
Deferred financing costs	(75,523)
Payments on equipment lease	(21,933)	(21,932)
Proceeds from term loan		10,680,000
Proceeds from issuance of convertible note warrants	1,354
Settlement of fractional common shares	(2,925)
Proceeds from convertible notes	4,500,000
Proceeds from initial public offering	47,654,190
Net cash provided by financing activities	51,095,229	16,708,150
(Decrease) increase in cash and cash equivalents	(1,015,249)	5,879,191
Cash and cash equivalents at beginning of period	3,613,392	1,815,289
Cash and cash equivalents at end of period	2,598,143	7,694,480
Noncash investing and financing activities
Accretion of preferred stock issuance costs	35,046	71,175
Accretion of Series D and E redeemable convertible preferred stock dividends	1,165,932	2,405,987
Deferred offering costs reclassified to distributions in excess of capital	2,297,079
Accrual of deferred offering and finance costs		657,499
Allocation of Series E warrant convertible notes debt discount	741,828	301,507
Conversion of convertible notes and related accrued interest to common stock	4,544,384
Fixed asset purchases payable at period end	272,847
Reclassification of convertible preferred stock liability warrants to equity warrants	1,616,140
Supplemental cash flow information
Cash paid for interest	701,250	145,367
Series B
Noncash investing and financing activities
Adjustment to Series B book value		112,903
Common Stock
Noncash investing and financing activities
Conversion of convertible preferred stock to common stock	57,356,049
Series D and Series E Warrants
Noncash investing and financing activities
Net exercise of Series D and Series E warrants	95,914
Series E Warrants
Noncash investing and financing activities
Accretion of Series E warrant discount	127,616	251,893
Series E Preferred Stock
Financing activities
Proceeds from sale of preferred stock, net of issuance costs		$ 7,428,307
Noncash investing and financing activities
Net exercise of Series D and Series E warrants	$ 11,312

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Description of Business	Note 1. Description of Business HTG Molecular Diagnostics, Inc. (the “Company”) is a commercial stage company that developed and markets a novel technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge platform, consisting of instrumentation (including HTG Edge and HTG EdgeSeq systems), consumables and software analytics, is used in sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. The Company’s HTG Edge platform automates the molecular profiling of genes and gene activity using its proprietary nuclease protection chemistry on a wide variety of biological samples. The Company derives revenue from the sale of instruments, consumables and related services. The Company operates in one segment and its customers are primarily located in the United States. For the three and nine months ended September 30, 2015, approximately 24% and 11%, respectively, of the Company’s revenue was generated from sales to customers located outside of the United States, compared to 7% and 18%, respectively, for the three and nine months ended September 30, 2014.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Note 2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying interim unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect the accounts of the Company as of September 30, 2015. Accordingly they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America (“GAAP”) for complete financial statements. The accompanying interim unaudited, condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented. The unaudited condensed balance sheet at December 31, 2014 has been derived from the audited consolidated financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations. Reverse Stock Split On April 27, 2015, the Company effected a one-for-107.39 reverse stock split of its outstanding common stock. All applicable common share and per common share information has been retroactively adjusted to reflect the effect of this reverse stock split. The reverse stock split did not change the number of shares of convertible preferred stock outstanding, but did affect the conversion ratios associated with the convertible preferred stock. Initial On May 11, 2015, the Company successfully completed its initial public offering (“IPO”), in which the Company sold 3,570,000 shares of common stock at $14.00 per share for total gross proceeds of approximately $50 million. An additional 90,076 shares of common stock were subsequently sold pursuant to the partial exercise by the underwriters of their over-allotment option resulting in additional gross proceeds of approximately $1.3 million. After underwriters’ fees and commissions and other expenses of the offering, the Company’s aggregate net proceeds were approximately $45.4 million. All outstanding shares of the Company’s redeemable convertible preferred stock converted into shares of common stock in connection with the IPO. Following the IPO, there were no shares of preferred stock outstanding. Liquidity The Company expects that the net proceeds from the IPO and its pre-existing cash and cash equivalents, together with interest thereon, will be sufficient to fund its operations for at least the next 12 months. However, the Company has had recurring operating losses and negative cash flows from operations since its inception. As such, the Company expects that it will need to raise additional equity or debt capital at some point in the future until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional equity or debt financing will be available on acceptable terms, or at all, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. The results of operations for the nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the full fiscal year or any other period. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, the value of the warrant liability, the resolution of uncertain tax positions, income tax valuation allowances, recovery of long-lived assets and provisions for doubtful accounts, inventory obsolescence and inventory valuation. Actual results could materially differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash and cash equivalents. Cash and cash equivalents consist of cash on deposit with financial institutions, money market instruments and high credit quality corporate debt securities purchased with a term of three months or less. Investments The Company classifies its securities as available-for-sale, which are reported at estimated fair value with unrealized gains and losses included in accumulated other comprehensive income, net of tax. Realized gains, realized losses and declines in value of securities judged to be other-than-temporary, are included in other income (expense). The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Interest and dividends earned on all securities are included in other income (expense). Investments in securities with maturities of less than one year, or where management’s intent is to use the investments to fund current operations, or to make them available for current operations, are classified as short-term investments. If the estimated fair value of a security is below its carrying value, the Company evaluates whether it is more likely than not that it will sell the security before its anticipated recovery in market value and whether evidence indicating that the cost of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. The Company also evaluates whether or not it intends to sell the investment. If the impairment is considered to be other-than-temporary, the security is written down to its estimated fair value. In addition, the Company considers whether credit losses exist for any securities. A credit loss exists if the present value of cash flows expected to be collected is less than the amortized cost basis of the security. Other-than-temporary declines in estimated fair value and credit losses are charged against other income (expense). Accounts Receivable, net Accounts receivable represent valid claims against debtors and have been reported net of an allowance for doubtful accounts of $129,922 and $85,068 at September 30, 2015 and December 31, 2014, respectively. Management reviews accounts receivable to identify where collectability may not be probable based on the specific identification method. Bad debt expense, net of recoveries, was $11,000 and $44,854 for the three and nine months ended September 30, 2015, respectively, and $15,000 and $117,467 for the three and nine months ended September 30, 2014, respectively. Inventory, net Inventory, consisting of raw materials and finished goods, is stated at the lower of cost (first-in, first-out) or market. The Company reserves or writes down its inventory for estimated obsolescence, inventory in excess of reasonably expected near term sales or unmarketable inventory, in an amount equal to the difference between the cost of inventory and the estimated market value, based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable. For the three and nine months ended September 30, 2015, the Company recorded an increase in the inventory reserve of $62,872 and $273,752, respectively, to adjust for estimated shrinkage and excess inventory. For the three and nine months ended September 30, 2014, the Company recorded a decrease in the inventory reserve of $536,119 and $536,119, respectively. These amounts were recorded within cost of revenue for each year. During the quarter ended March 31, 2015, the Company determined that the average period of time customers use to evaluate the Company’s equipment generally ranges from 90 to 180 days, and in certain circumstances the evaluation period may need to be extended beyond that period. HTG Edge or HTG EdgeSeq instruments at customer locations under evaluation agreements are included in finished goods inventory. Equipment that is under evaluation for purchase remains in inventory as the Company maintains title to the equipment throughout the evaluation period. If the customer has not completed the purchase of the instrument by the end of the initial evaluation period, the Company will determine whether to extend the evaluation period or have the equipment returned to the Company. However, in no case will the evaluation period exceed one year. If the customer has not purchased the equipment or entered into a reagent agreement with the Company after evaluating for one year, the cost of the equipment is written off to cost of revenue if the customer is allowed to continue use of the equipment. Prior to January 1, 2015, the Company recorded equipment under evaluation more than 90 days in property and equipment. The Company accordingly has reclassified from property and equipment to inventory field equipment with a net book value of $210,606 at December 31, 2014 under evaluation at that time for longer than 90 days and less than one year. Property and Equipment, net Property and equipment are stated at historical cost and depreciated over their useful lives, which range from three to five years, using the straight-line method. Leasehold improvements are amortized using the straight-line method over the lesser of the remaining lease term or the estimated useful life. Field equipment is amortized using the straight-line method over the lesser of the period of the related reagent agreement or the estimated useful life. Depreciation and leasehold improvement amortization expense was $174,390 and $473,799 for the three and nine months ended September 30, 2015, respectively, and $120,506 and $349,518 for the three and nine months ended September 30, 2014, respectively. Costs incurred in the development and installation of software for internal use are expensed or capitalized, depending on whether they are incurred in the preliminary project stage (expensed), application development stage (capitalized), or post-implementation stage (expensed). Amounts capitalized following project completion are amortized on a straight-line basis over the useful life of the developed asset, which is generally three years. There was no amortization expense for capitalized software costs for the three and nine months ended September 30, 2015. Amortization expense for capitalized software costs was $3,896 and $15,583 for the three and nine months ended September 30, 2014, respectively. Fair Value of Financial Instruments The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value. The fair value for securities held is determined using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. The carrying amounts of the Company’s asset-secured growth capital term loan (the “Growth Term Loan”) and convertible notes were estimated using Level 3 inputs and approximate fair value since the interest rate approximates the market rate for debt securities with similar terms and risk characteristics. Stock Issuance Costs Certain costs incurred in connection with the issuance of the Company’s redeemable convertible preferred stock (the “Convertible Preferred Stock”) have been deferred and are being accreted. Stock issuance costs have historically been accreted to distributions in excess of capital using the effective interest method. Accretion was $0 and $35,046 for the three and nine months ended September 30, 2015, respectively, and $19,488 and $71,175 for the three and nine months ended September 30, 2014, respectively. Upon automatic conversion of the Convertible Preferred Stock to common stock in connection with the closing of the Company’s IPO in May 2015, issuance costs were no longer accreted. Stock issuance cost for the three and six months ended June 30, 2014 included in the second quarter 2015 Form 10Q filing was overstated by an immaterial amount of $137,094. This resulted in an overstatement of the net loss per share attributable to common stockholders of $1.42 per share for the three and six months ended June 30, 2014. Deferred Financing Costs and Debt Discounts Certain costs incurred in connection with the Growth Term Loan have been deferred and are being amortized. Debt issuance costs and debt discount are amortized over the term of the Growth Term Loan using the effective interest method. In addition, prior to the IPO, costs incurred in connection with the issuance of notes under the Company’s two note and warrant purchase agreements dated December 30, 2014 (the “Note Agreements”) in February and March 2015 were capitalized and amortized over the term of the Note Agreements using the straight-line accretion method, which approximated the effective interest method in this instance. The Company has recorded approximately $59,582 and $75,131 of deferred financing costs in the accompanying condensed balance sheets as of September 30, 2015 and December 31, 2014, respectively. Deferred financing cost amortization expense for the three and nine month periods ended September 30, 2015 was $4,523 and $37,461 respectively. Deferred financing cost amortization was $2,700 for the three and nine months ended September 30, 2014. Amortization of growth term loan discount was $31,595 and $120,627 for the three and nine months ended September 30, 2015, respectively, and is included in interest expense in the accompanying condensed statements of operations. Amortization of the Note Agreement discount was $0 and $90,222 for the three and nine months ended September 30, 2015, respectively, and is included in interest expense in the accompanying condensed statements of operations. The Company compared the value of the common stock issued to settle the debt with the carrying amount of the debt at the IPO closing date of May 2015, net of unamortized discount. The Company recorded a loss on settlement of convertible debt of $705,217, comprised of $651,606 to write off unamortized discount and $53,611 to write off unamortized deferred financing costs relating to the convertible notes which were settled with common stock at the IPO, in the accompanying condensed statements of operations for the three and nine months ended September 30, 2015, respectively. Growth term loan discount accretion was $16,125 for the three and six months ended September 30, 2014, and there was no convertible note discount accretion for the three and nine months ended September 30, 2014. Deferred Offering Costs Deferred offering costs represent legal, accounting and other direct costs related to the IPO, which was completed in May 2015. In accounting for the IPO in May 2015, direct offering costs of approximately $2.3 million were reclassified to additional paid-in capital and are shown, along with underwriters’ fees paid, net against IPO proceeds received. The Company recorded $0 and $1.3 million of deferred offering costs as a non-current asset in the accompanying condensed balance sheets as of September 30, 2015 and December 31, 2014, respectively. Deferred Revenue Deferred revenue represents cash receipts for products or services to be provided in future periods. When products are delivered or services are rendered, deferred revenue is then recognized as earned. Revenue Recognition The Company recognizes revenue from the sale of instruments, consumables and related services when the following four basic criteria are met: (1) a contract has been entered into with a customer or persuasive evidence of an arrangement exists, (2) delivery has occurred or services rendered, (3) the fee is fixed and determinable, and (4) collectability is reasonably assured. Sale of instruments and consumables Instrument product revenue is generally recognized upon installation and calibration by our field service engineers, unless the customer has specified any other acceptance criteria. The sale of instruments and related installation and calibration are considered to be one unit of accounting, as instruments are required to be professionally installed and calibrated before use. Installation generally occurs within a week of shipment. Consumables are considered to be separate units of accounting as they are sold separately. Consumables revenue is recognized upon transfer of ownership, which is generally upon shipment. The Company’s standard term and conditions provide that no right of return exists for instruments or consumables. Shipping and handling fees charged to the Company’s customers for instruments and consumables shipped are included in the condensed statements of operations as part of product revenue. Shipping and handling costs for sold products shipped to the Company’s customers are included on the condensed statements of operations as part of cost of revenue. When a contract involves multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting. The Company performs this evaluation at the inception of an arrangement and as each item is delivered in the arrangement. Generally, the Company accounts for a deliverable (or a group of deliverables) separately if the delivered item has stand-alone value to the customer, the customer is given a general right of return relative to the delivered item, and delivery or performance of the undelivered item or service is probable and substantially in the Company’s control. When multiple elements can be separated into separate units of accounting, arrangement consideration is allocated at the inception of the arrangement, based on each deliverables’ relative selling price. All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract. The Company provides instruments to certain customers under a reagent agreement. Under these agreements, the Company installs instruments in the customer’s facility without a fee and the customer agrees to purchase consumable products at a stated price over the term of the agreement; in some instances the agreements do not contain a minimum purchase requirement. Terms range from several months to multiple years and may automatically renew in several month or multiple year increments unless either party notifies the other in advance that the agreement will not renew. This represents a multiple element arrangement and because all consideration under the reagent agreement is contingent on the sale of consumables, no consideration has been allocated to the instrument and no revenue has been recognized upon installation of the instrument. The Company expects to recover the cost of the instrument under the agreement through the fees charged for consumables, to the extent sold, over the term of the agreement. Revenue is recognized as consumables are shipped. In reagent rental agreements, the Company retains title to the instrument and title is transferred to the customer at no additional charge at the conclusion of the initial arrangement. Because the pattern of revenue from the arrangement cannot be reasonably estimated, the cost of the instrument is amortized on a straight-line basis over the term of the arrangement, unless there is no minimum consumable product purchase in which case the instrument would be expensed as cost of goods sold. Cost to maintain the instrument while title remains with the Company is charged to cost of revenue as incurred. The Company offers customers the opportunity to purchase separately-priced extended warranty contracts to provide for service upon conclusion of the standard one-year warranty period. The revenue from these contracts is recorded as a component of deferred revenue in the accompanying condensed balance sheets at the inception of the contract and is recognized as revenue over the contract service period. Service Revenue For contracts related to custom panel design services and sample processing, the Company utilizes a proportional performance revenue recognition model, under which revenue is recognized as performance occurs based on the relative outputs of the performance that have occurred up to that point in time under the respective agreement. The Company includes all applicable costs incurred related to custom panel design services, including research and development costs and general and administrative expenses, in cost of revenue. The Company also provides contract research services under cost plus fixed fee government contracts. Revenue is recognized under government contracts using the percentage-of-completion method of accounting. Under the percentage-of-completion method, contract research revenue is recognized as the work progresses and services are rendered and costs are incurred. The fixed fee is recognized in proportion to costs incurred compared to total estimated costs. The Company includes all applicable costs incurred from government contracts, including general and administrative expenses on government contracts, in cost of revenue. Anticipated losses, if any, on contracts are charged to earnings as soon as they are identified. Anticipated losses cover all costs allocable to contracts. Revenue arising from claims or change orders is recorded either as income or as an offset against a potential loss only when the amount of the claim can be estimated and its realization is probable. Other Revenue Other revenue includes license and grant revenue. License revenue is generated from the licensing of the Company’s internally developed intellectual property to third parties. The revenue may be generated by nonrefundable up-front payments and license fees, milestone and other contingent payments, or royalties based on sales of commercialized products. Licensing fees are recognized on a straight-line basis over the term of the license agreement for agreements requiring specific continuing performance obligations with deferral of all or a portion of these fees. If it cannot be concluded that a license fee is fixed or determinable at the outset of an arrangement, amounts are recognized as income as payments from third parties become due. No licensing fees were included in other revenue for the three and nine months ended September 30, 2015 and 2014. Grant revenue is earned when expenditures relating to the projects under these awards are incurred. Product Warranty The Company generally provides a one-year warranty on its HTG Edge and HTG EdgeSeq systems covering the performance of system hardware and software in conformance with customer specifications under normal use and protecting against defects in materials and workmanship. The Company may, at its option, replace, repair or exchange products covered under valid warranty claims. A provision for estimated warranty costs is recognized at the time of sale, through Cost of Revenue, based upon recent historical experience and other relevant information as it becomes available. The Company continuously assesses the adequacy of its product warranty accrual by reviewing actual claims and makes adjustments to the provision as needed. Due to a lack of historical data and a low rate of warranty claims, the Company had not recorded any liability for product warranty prior to the current period. Note 12 “Commitments and Contingencies” contains additional information relating to the Company’s product warranties. Research and Development Expenses Research and development expenses represent both costs incurred internally for research and development activities and costs incurred externally to fund research activities. All research and development costs are expensed as incurred. During the quarter ended September 30, 2015, the Company entered into a Development and Professional Services agreement with Invetech PTY Ltd. (Note 7) for the development of its low volume throughput HTG EdgeSeq platform, for which $150,000 of research and development expense was recorded for the three and nine months ended September 30, 2015. Share-Based Compensation The Company recognizes expense for share-based payments to employees, including grants of stock options and restricted stock units, based on the fair value of awards on the date of grant. The fair value of each employee stock option granted pursuant to the Company’s equity incentive plans is estimated on the date of grant using the Black-Scholes option pricing model. The determination of the fair value of share-based payment awards utilizing the Black-Scholes option pricing model is affected by the fair value of the Company’s stock price and a number of assumptions, including volatility, expected term, risk-free interest rate, and dividend yield. Generally these assumptions are based on historical information and judgment is required to determine if historical trends may be indicators of future outcomes. Employee stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates and an adjustment to stock-based compensation expense will be recognized at that time. Changes to assumptions used in Black-Scholes option valuation calculation and the forfeiture rate could significantly impact the compensation expense recognized by the Company. The Company uses fair value to account for restricted stock units (RSUs). The RSUs are valued based on the quoted market price of common stock on the date of grant and amortized ratably over the life of the award. For share-based payments to nonemployee consultants, the fair value of the share-based consideration issued is used to measure the transaction, as the Company believes this to be a more reliable measure of fair value than the services received. The fair value of the award is measured at the fair value of the Company’s stock options on the date that the commitment for performance by the nonemployee consultant has been reached or performance is complete. Stock-based compensation costs are recognized as expense over the requisite service period, which is generally the vesting period for awards, on a straight-line basis. Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and uncollateralized accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The Company sells its instruments, consumables, sample processing services, custom panel design services and contract research services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The top three customers accounted for 26%, 16% and 12% of the Company’s revenue for the three months ended September 30, 2015, compared with 19%, 19% and 5% for the three months ended September 30, 2014. The largest two customers accounted for 29% and 10% of the Company’s revenue for the nine months ended September 30, 2015. The largest three customers accounted for 12%, 10% and 9% for the nine months ended September 30, 2014. The Company derived 0% and 12% of its total revenue from grants and contracts, primarily from one organization during the three and nine month periods ended September 30, 2015, respectively. 27% and 32% of total revenue was derived from grants and contracts primarily from one organization, during the three and nine month periods ended September 30, 2014, respectively. The largest two customers accounted for approximately 23% and 23% of the Company’s net accounts receivable as of September 30, 2015. One customer accounted for approximately 31% of the Company’s net accounts receivable at December 31, 2014. The Company currently relies on a single vendor to manufacture its HTG Edge processor and reader and HTG EdgeSeq processor and additional single suppliers to supply subcomponents used in the processor. A loss of any of these suppliers could significantly delay the delivery of HTG Edge systems, which in turn would materially affect the Company’s ability to generate revenue. New Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing GAAP. The revised revenue standard is effective for public entities for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of our pending adoption of ASU 2014-09 on our financial statements and has not yet determined the method by which we will adopt the standard. In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Going Concern (“ASU 2014-15”). ASU 2014-15 provides GAAP guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The standard will be effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company does not believe the adoption of this standard will have a significant impact on the Company’s financial statements. In April 2015, the FASB issued Accounting Standards Update No. 2015-03, Interest – Imputation of Interest: Simplifying the presentation of Debt Issuance Costs (“ASU 2015-03”). The standard requires entities to present debt issuance costs on the balance sheet as a direct deduction from the related debt liability rather than as an asset, and the amortization is reported as interest expense. The result of application of this guidance would be to reduce the deferred financing costs balance, with a corresponding reduction to the long term liabilities to which the debt issuance costs relate in the condensed balance sheets. The standard does not affect recognition and measurement of debt issuance costs. The Company expects to adopt ASU 2015-03 on January 1, 2016. In July 2015, the FASB issued Accounting Standards Update 2015-11, Inventory: Simplifying the

Inventory

Inventory	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Inventory	Note 3. Inventory Inventory, net of allowance, consisted of the following as of the date indicated: September 30, December 31, 2015 2014 Raw materials $ 971,118 $ 1,029,927 Work in process 22 — Finished goods 1,295,042 655,887 $ 2,266,182 $ 1,685,814

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 4. Fair Value Instruments Fair value measurements used by the Company for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements are based on the premise that fair value represents an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the following three-tier fair value hierarchy has been used in determining the inputs used in measuring fair value: Level 1 – Quoted process in active markets for identical assets or liabilities on the reporting date. Financial assets in Level 1 include the amounts held in money market accounts classified as cash equivalents. Level 2 – Pricing inputs are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Pricing inputs are generally unobservable and include situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require management’s judgment or estimation of assumptions that market participants would use in pricing the assets or liabilities. The fair values are therefore determined using factors that involve considerable judgment and interpretations, including but not limited to private and public comparables, third-party appraisals, discounted cash flow models, and fund manager estimates. Financial liabilities in this category include the Company’s Preferred Stock warrants. We measure the fair values of these assets and liabilities based on prices provided by independent market participant that are based on observable inputs using market-based valuation techniques. These valuation models and analytical tools use market pricing or similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company did not adjust any of the valuations received from these third parties with respect to any of its level 1 securities at September 30, 2015 or December 31, 2014. Our portfolio of securities comprises U.S. Treasuries, U.S. government sponsored agency obligations and high credit quality corporate debt securities classified as available-for-sale securities. Initial investment in available-for-sale securities was made during the quarter ended June 30, 2015 as a result of funding received through the Company’s IPO. Unrealized gains and losses are included in other comprehensive income (loss). Realized gains, realized losses and declines in value of securities judged to be other-than-temporary, will be included in other income (expense). Financial assets and liabilities measured at fair value are classified in their entirety into the fair value hierarchy, based on the lowest level input significant to the fair value measurement. The following table classifies the Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2015 and December 31, 2014, respectively into the fair value hierarchy: Balance at September 30, 2015 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 2,573,882 $ — $ — $ 2,573,882 Investments at fair value U.S. government obligations $ 3,308,573 $ — $ — $ 3,308,573 U.S. government agency obligations $ — $ 14,715,616 $ — $ 14,715,616 Corporate debt securities $ — $ 18,454,522 $ — $ 18,454,522 Balance at December 31, 2014 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 3,608,890 $ — $ 3,608,890 Liabilities included in: Growth Term Loan warrants $ — $ — $ 301,508 $ 301,508 Convertible Preferred Stock warrants $ — $ — $ 429,035 $ 429,035 There are no other financial instruments subject to fair value measurement on a recurring basis. Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period. There were no transfers between levels for the three and nine months ended September 30, 2015 or for the year ended December 31, 2014. Level 1 instruments include investments in money market funds and U.S. Treasuries. These instruments are valued using quoted market prices for identical unrestricted instruments in active markets. The Company defines active markets for debt instruments based on both the average daily trading volume and the number of days with trading activity. Level 2 instruments include U.S. Government agency obligations and corporate debt securities. Valuations of Level 2 instruments can be verified to quoted prices, recent trading activity for identical or similar instruments, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. Consideration is given to the nature of the quotations (e.g. indicative or firm) and the relationship of recent market activity to the prices provided from alternative pricing sources. The Company used its May 2015 IPO pricing as an input for measurement of the fair value of its Level 3 preferred stock warrant liabilities at May 11, 2015 and the Black-Scholes option pricing model, and other valuation models for measuring the fair value of its Level 3 Preferred Stock warrant liabilities at December 31, 2014. The outstanding Preferred Stock warrants were converted to common stock warrants in connection with the closing of the Company’s IPO. The Company’s warrant liabilities at December 31, 2014 were categorized as Level 3 because they were valued based on unobservable inputs and management judgment due to the absence of quoted market prices, inherent lack of liquidity and the long-term nature of such financial instruments. As a result of their conversion to common stock warrants on May 11, 2015 with our IPO, there were no warrant liabilities outstanding at September 30, 2015. The December 31, 2014 fair value assessments used the Black-Sholes option pricing model using the following assumptions: December 31, 2014 Fair value of Series B/C/D Stock and Series E Stock shares on grant date or measurement date $0.14 - $0.22 Exercise price $0.01 - $0.346 Expected risk-free interest rate 1.20% Expected volatility 70% Expected term 4.1 years Expected dividend yield 0 - 8% The volatility assumption is based on the volatility of publicly traded industry competitors as adjusted for future expectations. The expected term was based on the Company’s historical experience and future expectations with regard to the exercise of the Convertible Preferred Stock warrants and the probability of conversion of the underlying Convertible Preferred Stock. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of the warrants. At December 31, 2014 the fair value of the Convertible Preferred Stock was determined by a valuation model that considered both income and market-based valuations of the Company’s enterprise value. The expected dividend yield at December 31, 2014 is consistent with the dividend rate on the Convertible Preferred Stock. The assumptions used in the Black-Scholes option pricing model are inherently subjective and involve significant judgment. Any change in the fair value was recognized as a component of other income (expense) in the condensed statements of operations. A reconciliation of the beginning and ending liabilities measured at fair value and classified as Level 3 inputs for the nine months ended September 30, 2015 and September 30, 2014 are as follows: September 30, 2015 2014 Beginning balance $ 730,543 $ 44,120 Issuance of Series E Convertible Preferred Stock Warrants — 2,191,507 Exercise of Series E Convertible Preferred Stock Warrants (4,116 ) (1,890,000 ) Exercise of Series D Convertible Preferred Stock Warrants (91,798 ) — Reclassification of Series C-2 Convertible Preferred Stock Warrants to Common Stock Warrants (555 ) — Reclassification of Growth Term Loan Warrants to Common Warrants (229,550 ) — Issuance of Convertible Note Warrants 741,828 — Reclassification of Convertible Note Warrants to Common Stock Warrants (1,386,035 ) — Change in Convertible Preferred Stock warrant valuation 239,683 56,322 Ending balance $ — $ 401,949

Available for Sale Securities

Available for Sale Securities	9 Months Ended
	Sep. 30, 2015
Investments Debt And Equity Securities [Abstract]
Available for Sale Securities	Note 5. Available for Sale Securities The following is a summary of the Company’s available-for-sale securities at September 30, 2015: Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) US Treasury securities and obligations of US government agencies $ 18,015,477 $ 8,712 $ — $ 18,024,189 Corporate securities 18,458,480 1,179 (5,137 ) 18,454,522 Total available-for-sale securities $ 36,473,957 $ 9,891 $ (5,137 ) $ 36,478,711 The net adjustment to unrealized holding gains (losses) on available-for-sale securities in other comprehensive income totaled $4,754 and $0, for the nine months ended September 30, 2015 and 2014, respectively. Contractual maturities of debt investment securities at September 30, 2015, are shown below. Expected maturities will differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. Under 1 Year 1 to 2 Years Total US Treasury securities and obligations of US government agencies $ 13,085,633 $ 4,938,556 $ 18,024,189 Corporate securities 15,626,126 2,828,396 18,454,522 Total available-for-sale securities $ 28,711,759 $ 7,766,952 $ 36,478,711 The following tables shows the gross unrealized losses and fair values of the Company’s investments that have unrealized losses, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position as of September 30, 2015: Under 1 Year 1 to 2 Years Total Gross Gross Gross Fair Unrealized Fair Unrealized Fair Unrealized Value Losses Value Losses Value Losses Corporate securities $ 3,430,702 $ 5,137 $ — $ — $ 3,430,702 $ 5,137 Total available-for-sale securities with unrealized losses $ 3,430,702 $ 5,137 $ — $ — $ 3,430,702 $ 5,137 For debt securities, management determines whether it intends to sell or if it is more likely than not that it will be required to sell impaired securities. This determination considers current and forecasted liquidity requirements, regulatory and capital requirements and securities portfolio management. For all impaired debt securities for which there was no intent or expected requirement to sell, the evaluation considers all available evidence to assess whether it is likely the amortized cost value will be recovered. The Company conducts a regular assessment of its debt securities with unrealized losses to determine whether securities have other-than-temporary impairment considering, among other factors, the nature of the securities, credit rating or financial condition of the issuer, the extent and duration of the unrealized loss, expected cash flows of underlying collateral, market conditions and whether the Company intends to sell or it is more likely than not the Company will be required to sell the debt securities. The Company did not have any other-than-temporary impairment in its corporate debt securities for the period ended September 30, 2015. The Company began investing in marketable securities upon receipt of proceeds from its IPO in May 2015. Prior to that date, the Company did not have any investments in marketable securities.

Debt Obligations

Debt Obligations	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Debt Obligations	Note 6. Debt Obligations. Growth Term Loan In August 2014, the Company entered into the Growth Term Loan with a syndicate of two lending institutions. The first tranche of the Growth Term Loan (“Growth Term Loan A”) of $11.0 million was funded at the August 2014 closing. A second tranche of $5.0 million (“Growth Term Loan B”) was initially available to be drawn until July 4, 2015. In August 2015, the Company and its lenders amended the Growth Term Loan agreement to extend the availability of Growth Term Loan B until March 31, 2016. The Company received the Growth Term Loan A proceeds net of a $0.3 million original issue discount. The Company also recorded a discount for the issuance of warrants with Growth Term Loan A (See Note 9). The original issuance discount and warrant discount are being amortized, using the effective interest method, over the term of the Growth Term Loan A. Amortization expense was $31,595 and $120,627 for the three and nine months ended September 30, 2015, respectively, and is included in interest expense in the accompanying condensed statements of operations. Amortization expense was $16,125 for the three and nine months ended September 30, 2014. The Growth Term Loan A bears interest at the fixed rate of 8.5% and matures in September 2018. Pursuant to the August 2015 amendment to the Growth Term Loan agreement, the Company will have monthly interest-only payment obligations until April 1, 2016. Following the interest-only payment period, equal monthly payments of $408,296 consisting of principal and interest amortized over the remaining term of the loan through September 2018 will be due. The condensed balance sheets and the principal repayments table below have been adjusted to reflect this amended payment schedule. The August 2015 amendment further changed the prepayment fee schedule for Growth Term Loan A such that the Company will be obligated to pay a prepayment fee equal to (i) 3% of the principal amount prepaid if the growth term loan is prepaid on or before the first anniversary of the August 2015 amendment, (ii) 2% of the principal amount repaid if the growth term loan is prepaid after the first anniversary but on or prior to the second anniversary of the August 2015 amendment and (iii) 1% of the principal amount repaid if the growth term loan is repaid after the second anniversary of the August 2015 amendment and prior to maturity. The amendment also increased the final payment percentage to 4.75%. The Growth Term Loan requires the Company to maintain compliance with specific reporting covenants and does not require financial covenants. The Growth Term Loan is secured by a lien covering substantially all of the Company’s assets, excluding patents, trademarks and other intellectual property rights (except for rights to payment related to the sale, licensing or disposition of such intellectual property rights) and certain other specified property. The Company paid $0.1 million in financing costs upon entering the Growth Term Loan. The agreement included Convertible Preferred Stock warrants to purchase 2,512,562 shares of Series E Stock (the “Series E Loan Warrants”) at a price of $0.2189 per share or at the purchase price of the next round of equity sold if no further shares of Series E Stock were sold. The warrants to purchase shares of Series E Stock expire on August 22, 2024 (See Note 9) and were automatically converted to warrants for common stock upon completion of the Company’s IPO in May 2015. The principal repayments due under the term loan as of September 30, 2015, are as follows: 2015 $ — 2016 3,059,068 2017 4,393,103 2018 3,547,829 Total Growth Term Loan payments 11,000,000 Less discount (416,204 ) Plus final fee premium 172,599 Total Growth Term Loan, net $ 10,756,395 Convertible Notes On December 30, 2014, the Company entered into two, separate subordinated convertible promissory note agreements (“the Note Agreements”). The Note Agreements provided that upon a qualified equity financing, pursuant to which the Company raised either through a qualified initial public offering of common stock or through a qualifying private placement of Convertible Preferred Stock, gross offering proceeds of at least $20,000,000 from the sale of shares to new investors, the outstanding principal amount and all accrued but unpaid interest under convertible notes issued pursuant to the Note Agreements would automatically convert into shares of common stock or preferred stock, whichever was sold in the offering. The number of shares into which the convertible notes were convertible was equal to the outstanding principal and accrued interest divided by the price per share paid by investors purchasing such newly issued equity securities. The Note Agreements also provided that in the event of a sale of the Company, the holders could elect to receive two times the outstanding principal and accrued interest or the number of shares of Series E Convertible Preferred Stock as was equal to the outstanding principal and accrued interest divided by $0.2189. Under the first Note Agreement, the Company was able to issue up to $7,339,165 of notes to existing investors at five future, individual closings of up to $1,500,000 each upon ten days’ notice to participating investors . Under the second Note Agreement, the Company was able to issue up to $6,203,971 of subordinated convertible notes to existing investors at four individual closings of up to $1,703,971 each upon ten days’ notice to participating investors. When issued, the notes would bear annual interest at 8% and mature on March 31, 2016. In addition, pursuant to the second Note Agreement the Company issued to participating investors warrants to purchase up to 4,282,472 shares of Series E Convertible Preferred Stock at $0.2189 per share, discussed further in Note 9. Under each of the Note Agreements, the failure of a principal or major participating investor to invest their committed amount at each of the closings resulted in the conversion of a percentage of the investor’s preferred shares into common shares at the applicable conversion rates in effect pursuant to the Company’s restated certificate of incorporation. Under the first Note Agreement, failure of a principal investor to purchase their committed amount resulted in the conversion of their entire holdings of Convertible Preferred Stock into common stock, at conversion rates then in effect. Under the second Note Agreement, up to 80% of the total Convertible Preferred Stock held by such investor will be converted into common stock, at conversion rates then in effect. In addition, failure to purchase the full committed amount in any closing will result in the termination of the applicable investor’s warrants, in whole or in part, and the forgiveness and extinguishment of 80% of the aggregate principal amount of the applicable investor’s outstanding notes, if any. In the event the Company sold new shares of stock in a qualified initial public offering or preferred stock in a private placement, an investor’s failure to participate in the subsequent equity financing, in an amount equal to their applicable remaining committed amount under the Note Agreements, would result in the conversion of up to 80% of the non-participating investor’s aggregate Convertible Preferred Stock holding as of the closing date of the subsequent equity financing, along with a reduction of up to 80% of the non-participating investor’s warrants. Pursuant to the provisions of the second Note Agreement, certain preferred shares were optionally converted into common stock as of December 30, 2014. Certain provisions of the first Note Agreement terminate (including the investors’ obligations to purchase notes thereunder) immediately prior to the earlier to occur of the closing of (i) a qualified initial public offering or (ii) a qualified private placement. Certain provisions of the second Note Agreement terminate (including the investors’ obligations to purchase notes thereunder) immediately prior to the earlier to occur of (x) the time at which a registration statement covering a public offering of the Company’s securities under the Securities Act of 1933, as amended, becomes effective or (y) the initial closing of a qualified private placement. Such provisions of the Note Agreements (including the investors’ obligations to purchase notes thereunder) terminated in connection with the completion of the Company’s IPO. As of December 31, 2014, there were no borrowings under the Note Agreements. Draws under the first Note Agreement in February, March and April 2015 totaled $4.5 million through the Company’s IPO in May 2015. There were no draws under the second Note Agreement prior to the Company’s IPO in May 2015. The Company booked a $741,828 discount for the estimated fair value of warrants issued in connection with the debt (See Note 9). The warrant discount is being amortized, using the effective interest method, over the term of the Convertible Notes. Amortization expense of $0 and $90,222 for the three and nine months ended September 30, 2015, respectively, is included in the condensed statements of operations. There was no amortization expense for the three and nine months ended September 30, 2014. Settlement of Convertible Debt upon IPO Closing Upon closing of the Company’s IPO in May 2015, all outstanding principal ($4.5 million) and accrued interest under the convertible notes issued pursuant to the first Note Agreement was converted into 324,591 shares of common stock at a conversion price of $14.00 per share. The Company evaluated the terms of the Note Agreement at inception and concluded that it should be accounted for as share settled debt as it falls within the scope of ASC 480, “Distinguishing Liabilities from Equity”. While the issued debt Note Agreements contain multiple events that could trigger settlement at different values, the Company evaluated all of the possible outcomes and considered the qualified IPO outcome to be predominant at more than a 50% probability of occurrence. The IPO settlement triggering event settles the fixed monetary amount of the debt known at inception with a variable number of shares of common stock based on the price of the common stock at settlement and therefore meets the definition of share settled debt. The Company compared the value of the common stock issued to settle the debt with the carrying amount of the debt at the IPO closing date of May 2015, net of unamortized discount and deferred financing costs, and recorded a loss on settlement of debt of $705,217 in the accompanying condensed statements of operations for the three and nine months ended September 30, 2015. The value of the debt adjusted to the value of the common stock paid was reclassified from debt to equity.

Other Agreements

Other Agreements	9 Months Ended
	Sep. 30, 2015
Other Agreements [Abstract]
Other Agreements	Note 7. Other Agreements NuvoGen Obligation The Company entered into an asset purchase agreement in 2001, as amended, with NuvoGen Research, LLC (“NuvoGen”) to acquire certain intellectual property from NuvoGen. The Company accounted for the transaction as an asset acquisition. However, as the intellectual property was determined to not have an alternative future use, the upfront consideration was expensed. The Company exchanged upfront consideration of 600,000 shares of the Company’s common stock. The remaining cash consideration of $15,000,000 is to be paid by the Company through a percentage of applicable annual sales equal to the greater of a minimum annual payment or 6% of the Company’s applicable annual revenues. The obligation is non-interest bearing and was secured by certain patents and trademarks. Certain terms of the agreement were amended in November 2012 and February 2014. The Company recorded the obligation at the estimated present value of the future payments using a discount rate of 2.5%, the Company’s estimate of its effective borrowing rate for similar obligations. Unamortized debt discount was $335,402 and $564,634 at September 30, 2015 and December 31, 2014, respectively. Pursuant to the closing of the Growth Term Loan in August 2014 (See Note 6), the Company agreed to accelerate certain minimum payments pursuant to the asset purchase agreement and NuvoGen agreed to terminate its security interest in the originally pledged patents and trademarks. Remaining minimum payments that were otherwise due for 2014, 2015 and the first quarter of 2016, amounting to $868,750 were paid in advance. No further payment is due under the asset purchase agreement until the second quarter of 2016. The acceleration of payments did not significantly change the minimum cash flows and therefore had no significant accounting effect. There were no payments made to NuvoGen during the three and nine months ended September 30, 2015. NuvoGen was paid $981,250 and $1,206,250, respectively, during the three and nine months ended September 30, 2014. Discount accreted during the three and nine months ended September 30, 2015 was $51,481 and $229,232, respectively, and $46,867 and $141,551, during the three and nine months ended September 30, 2014, respectively. The remaining payments due to NuvoGen at September 30, 2015, are as follows: 2015 $ — 2016 543,750 2017 800,000 2018 400,000 2019 400,000 2020 and beyond 7,098,743 Total NuvoGen obligation payments 9,242,493 Less discount (335,402 ) Total NuvoGen obligation, net $ 8,907,091 Illumina, Inc. Agreement In October 2014, the Company entered into a development and component supply agreement with Illumina, Inc. for the development and worldwide commercialization by the Company of up to two complete diagnostic gene expression profiling tests for with Illumina’s diagnostic instruments, using components supplied by Illumina. The Company refers to these diagnostic gene expression profiling tests as IVD test kits. The IVD test kits may be used in two discrete testing fields chosen by the Company, one or both of which may relate to oncology for breast, lung, lymphoma or melanoma tumors, and up to one of which may relate to transplant, chronic obstructive pulmonary disease, or immunology/autoimmunity. The Company provided notice to Illumina of its first testing selections during the quarter ended March 31, 2015. If a second selection is to be selected, the Company must provide notice to Illumina of the Company’s second selected field within 24 months following the date of the agreement. Following the Company’s selection of the testing field for each IVD test kit, the Company and Illumina have agreed to negotiate a development plan for the development and regulatory approval of the applicable IVD test kit. Illumina has agreed to provide development and regulatory support as part of the plan. Upon mutual agreement of the first development plan, the Company will pay Illumina a fixed fee in the six-figure dollar range. The Company is also required to pay Illumina up to $1.0 million in the aggregate upon achievement of specified regulatory milestones relating to the IVD test kits. In addition, the Company has agreed to pay Illumina a single digit percentage royalty on net sales of any IVD test kits that the Company commercializes pursuant to the agreement. As of September 30, 2015 the first development plan had not been completed, however, it was subsequently finalized on October 29, 2015 (See Note 15). Ongoing research and development costs for these programs have been expensed as incurred and $0 has been paid to Illumina relating to this agreement as of September 30, 2015. The agreement will expire on the earlier of October 2019 or the date which the last to expire development plan under the agreement is completed. The Company may terminate the agreement at any time upon 90 days’ written notice and may terminate any development plan under the agreement upon 30 days’ prior written notice. Illumina may terminate the agreement upon 30 days’ prior written notice if the Company undergoes certain changes of control or immediately if the Company fails to select a testing field for an IVD test kit within 24 months following the date of the agreement. Either party may terminate the agreement upon the other party’s material breach of the agreement that remains uncured for 30 days, or upon the other party’s bankruptcy. Invetech PTY Ltd. Agreement In September 2015, the Company entered into a development and professional services agreement with Invetech PTY Ltd., for the conduct of research and development of a next generation automated sample library preparation instrument. This instrument is to be a low volume throughput version of the Company’s existing HTG EdgeSeq system technology and is being referred to as Project JANUS during development. The agreement requires the execution of a development plan for each stage of the project. Upon full execution and delivery of each development plan, the Company will pay Invetech development fee installments for that development plan. The initial installment of the development fee was earned in September 2015, resulting in $150,000 of research and development expense relating to this agreement being included in the condensed statements of operations for the three and nine months ended September 30, 2015. The agreement will remain in effect through completion of all tasks and acceptance of all deliverables under each development plan unless terminated earlier as provided for in the agreement.

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Net Loss per Share	Note 8. Net Loss Per Share Net loss attributable to common stockholders per share is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding. Outstanding stock options, warrants and Convertible Preferred Stock have not been included in the calculation of diluted net loss attributable to common stockholders per share because to do so would be anti-dilutive. Accordingly, the numerator and the denominator used in computing both basic and diluted net loss per share for each period are the same. The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share for the periods presented: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Numerator: Net loss $ (5,157,663 ) $ (3,307,329 ) $ (15,698,139 ) $ (9,819,746 ) Accretion of stock issuance costs — (19,488 ) (35,046 ) (71,175 ) Accretion of discount on Series E warrants — (94,893 ) (127,616 ) (251,893 ) Series E and D, Convertible Preferred Stock dividends — (837,225 ) (1,165,932 ) (2,405,987 ) Net loss attributable to common stockholders $ (5,157,663 ) $ (4,258,935 ) $ (17,026,733 ) $ (12,548,801 ) Denominator: Weighted-average common shares outstanding -basic and diluted 6,829,687 96,486 3,735,852 96,446 Net loss per share attributable to common stockholders, basic and diluted $ (0.76 ) $ (44.14 ) $ (4.56 ) $ (130.11 ) The following outstanding options, warrants and Convertible Preferred Stock were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Three and Nine Months Ended September 30, 2015 2014 Options to purchase common stock 590,139 542,435 Restricted stock units 27,500 — Convertible Preferred Stock (as converted) — 2,353,166 Convertible Preferred Stock warrants (as converted) — 51,863 Common stock warrant 170,587 931

Warrants

Warrants	9 Months Ended
	Sep. 30, 2015
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Warrants	Note 9. Warrants In connection with certain of its Convertible Preferred Stock issuances, convertible debt financings and other financing arrangements, the Company issued warrants for shares of its common stock and various issues of its Convertible Preferred Stock. On August 22, 2014, in connection with the Company’s entry into the Growth Term Loan, the Company issued to the lenders Series E Loan Warrants exercisable for an aggregate of 2,512,562 shares of Series E Convertible Preferred Stock at a price of $0.2189 per share. The warrants provided for cashless exercise at the option of the holders, and also contained provisions for the adjustment of the number of shares issuable upon the exercise of the warrant in the event of stock splits, recapitalizations, reclassifications, consolidations or dilutive issuances. In connection with the completion of the IPO in May 2015, the Series E Loan Warrants became exercisable for an aggregate of 23,396 shares of the Company’s common stock at an exercise price of $23.51 per share. The Series E Loan Warrants expire by their terms on August 22, 2024, provided that the warrants will be automatically exercised on a cashless basis upon expiration if not previously exercised if the fair market value of a share of the Company’s common stock exceeds the per share exercise price. The Company allocated the total proceeds of the Growth Term Loan and the Series E Loan Warrants based on the residual value method. Assumptions used to determine the initial fair value included fair value of shares of Series E Stock on grant date $0.31; Exercise price $0.2189; Expected risk-free interest rate 1.6%; Expected volatility 70.0%; Expected term 4.5 years; and Expected dividend yield 8.0%. The fair value of the Series E Warrants of $0.12 per share, or $301,507, was recorded as a discount on the Growth Term Loan to be accreted over the term of the Growth Term Loan using the effective interest method. The Company has historically accounted for the Series E Loan Warrants as liabilities as such warrants were indexed to shares that could be redeemed for cash outside the control of the Company. The preferred warrants were valued using the Black-Scholes option pricing model as of December 31, 2014. At December 31, 2014, the fair value of the Series E Loan Warrants was $301,507. Refer to Note 4 for assumptions used to value these warrants. On December 30, 2014, in connection with the Company’s Note and Warrant Purchase Agreements (Note 6) the Company agreed to issue warrants (the “Convertible Note Warrants”) exercisable for an aggregate of 9,311,586 shares of Series E Stock at a price of $0.2189 per share, for aggregate consideration of $1,354. The Convertible Note Warrants were issued on January 15, 2015. The warrants provide for cashless exercise at the option of the holders, and also contained provisions for the adjustment of the number of shares issuable upon the exercise of the warrant in the event of stock splits, recapitalizations, reclassifications, consolidations or dilutive issuances. The Convertible Note Warrants expire by their terms on January 15, 2022. As the Convertible Note Warrants were issued in conjunction with and in order to establish a lending facility commitment, they were being accounted for as a debt discount to be amortized over the life of the Note Agreements using the effective interest method and as a warrant liability, at fair value, as they were indexed to shares that could be redeemed for cash outside the control of the Company. The Company recorded the initial $741,828 of the Convertible Note Warrants using the Black-Scholes option pricing model and assumptions further described in Note 4, specifically using a 7 year term, a 1.6% risk free interest rate, 75% volatility, 0% dividend yield and a common stock price of $0.13 which is a pre-IPO equivalent to the Company’s $14.00 per share offering price in May 2015, which the Company considered to approximate the fair value at January 14, 2015 as the operations of the business had not changed during the intervening period. Upon closing of the IPO, the Company’s Convertible Preferred Stock warrants expired, were exchanged for common stock warrants or were exercised by the holders, depending on the terms of the respective agreements and actions of the holders. The Company computed the fair value of the warrants immediately prior to the conversion date and the change in fair value was recorded to loss from change in stock warrant valuation within the condensed statements of operations. The Company’s Series C-1 Convertible Preferred Stock warrants expired upon closing of the IPO as they were not exercised prior to or contemporaneously with the closing of the IPO. As of May 11, 2015, 1,290,350 Series C-1 preferred stock warrants were forfeited and cancelled as they were not exercised prior to the IPO. Each share of Convertible Preferred Stock outstanding immediately prior to the closing of the IPO automatically converted into shares of the Company’s common stock. Due to the conversion of the underlying Series C-2 Convertible Preferred Stock and Series E Convertible Preferred Stock into common stock, the Series C-2, Series E and Convertible Note preferred warrants became exercisable for common stock. Following conversion to common stock warrants, these warrants were determined to meet the criteria for equity classification. Upon completion of the IPO, and the conversion of the Company’s Series C-2 Convertible Preferred Stock into common stock, the Series C-2 Convertible Preferred Stock warrants converted to warrants for purchase of 1,488 shares of the Company’s common stock at an exercise price of $24.23 per share. The Convertible Note Warrants converted to warrants for the purchase of 144,772 shares of the Company’s common stock at the initial public offering price of $14.00 per share. Series E Loan Warrants converted to warrants for the purchase of 23,396 shares of the Company’s common stock at the IPO price of $14.00 per share. During 2015, all Series D Convertible Preferred Stock warrant holders elected to exercise their warrants, contingent and effective upon closing of the IPO. Upon completion of the IPO, the Company issued 723,050 shares of its Series D Convertible Preferred Stock upon the exercise of 769,059 outstanding warrants, for which it received aggregate cash consideration of approximately $1,752 for such exercises. Certain warrant holders elected to exercise pursuant to the terms of the net exercise provision of the warrant. For purposes of such net exercise, the fair market value of the Company’s common stock was equal to the IPO price of $14.00. The Series D Convertible Preferred Stock converted into 6,729 shares of the Company’s common stock on May 11, 2015. Security Number of Preferred and Common Warrants at December 31, 2014 Number of Common Warrants at September 30, 2015 Exercise Price/Share Expiration Date Series C-1 redeemable convertible preferred stock warrants 1,290,350 — $ 37.16 2016-2017 Series C-2 redeemable convertible preferred stock warrants 157,912 1,488 24.23 2015 Series D redeemable convertible preferred stock warrants 769,059 — 1.07 2020 Series E redeemable convertible preferred stock warrants 2,512,562 23,396 23.51 2024 Convertible note warrants — 144,772 14.00 2022 Common stock warrants 931 931 6.45 2019 The fair value of the Convertible Preferred Stock warrant liability was $0 and $730,543 at September 30, 2015 and December 31, 2014, respectively. During the three and nine months ended September 30, 2015 the Company recorded a loss of $0 and $239,683, respectively, on the change in fair value of the Convertible Preferred Stock warrants, as the fair value of all Convertible Preferred Stock warrants was updated prior to conversion at IPO, with the fair value change being charged to loss from change in stock warrant valuation in the condensed statements of operations. A loss of $0 and $56,323, respectively, was recorded during the three and nine months ended September 30, 2014 on the change in fair value of the Convertible Preferred Stock warrants. The Convertible Preferred Stock warrant liability for outstanding Series C-2, Series D and Series E warrants was reclassified to additional paid-in-capital and recorded as common stock warrants upon the closing of the Company’s IPO.

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Redeemable Convertible Preferred Stock	Note 10. Redeemable Convertible Preferred Stock On February 4, 2014, the Company entered into the Series E Convertible Preferred Stock and Warrant Purchase Agreement (the “Series E Agreement”) authorizing the sale and issuance of up to 99,132,024 shares of its Series E Stock for $0.2189 per share and warrants (the “Series E Warrants”) to purchase up to an aggregate of 33,044,008 shares of Series E Stock at an exercise price of $0.001 per share. Pursuant to the Series E Agreement, up to 49,566,012 shares of Series E Stock together with Series E Warrants to purchase up to an aggregate of 16,522,004 shares of Series E Stock would be offered at one or more closings of a first tranche and the remainder of which will be offered in a second tranche. As a result of the Series E Preferred Agreement, the Company’s authorized shares were increased to 600,000,000 shares of Common Stock and 472,083,383 shares of Convertible Preferred Stock. On February 4, 2014 the Company issued 34,099,476 shares of Series E Stock pursuant to the Series E Agreement at a price per share of $0.2189 per share. Along with the shares of Series E Stock, one Series E Warrant was issued for every three shares of Series E Stock purchased with a purchase price of $0.0001 per Series E Warrant and an exercise price of $0.001 per share of Series E Stock for a total of 11,366,486 Series E Warrants. Each Series E Stock purchaser was required to exercise the Series E Warrant in a simultaneous transaction with the purchase of shares of Series E Stock. Together with the Series E Warrants, the issuance of shares of Series E Stock and Series E Warrants resulted in gross proceeds to the Company of $7,476,879. On March 31, 2014, pursuant to a rights offering, the Company issued 354,062 shares of Series E Stock pursuant to the Series E Agreement at a price per share of $0.2189 per share. Along with the shares of Series E Stock, one Series E Warrant was issued for each three shares of Series E Stock purchased with a purchase price of $0.0001 per Series E Warrant and an exercise price of $0.001 per share of Series E Stock for a total of 118,017 Series E Warrants. Each Series E Stock purchaser was required to exercise the Series E Warrant in a simultaneous transaction with the purchase of shares of Series E Stock. Together with Series E Warrants, the issuance of shares of Series E Stock and Series E Warrants resulted in gross proceeds to the Company of $77,634. The Series E Agreement provided for a second tranche on or before November 30, 2014, contingent upon the achievement of certain milestones. It was determined that, given the nominal strike price of the Series E Warrants and the fact that the Series E Preferred Warrants were required to be exercised immediately upon issuance, the per share value of the Series E Warrants would be similar to the effective per share value of the Series E Stock, or $0.1645 per share. The second closing under the Series E Agreement, originally scheduled to occur on or before November 31, 2014, was replaced by an alternative financing in the form of subordinated convertible promissory notes as discussed further in Note 6. Each series of Convertible Preferred Stock had a par value of $0.001 per share. The Series D Convertible Preferred Stock and Series E Convertible Preferred Stock liquidation preference was equal to two times the original issue price of the Series D Convertible Preferred Stock or Series E Convertible Preferred Stock, respectively, plus any accrued but unpaid dividends whether or not declared. The Company has historically accreted up to the redemption amount and not the liquidation value, because additional amounts due under the liquidation rights was not considered probable at initial recording or as of the Company’s IPO in May 2015 or at December 31, 2014. The shares of each series of Convertible Preferred Stock historically had the right to redemption of their respective class of shares on a date beginning not prior to February 2019 (the “Series E Preferred Stock Redemption Date”). In order to effect each respective redemption, the holders of at least 60% of the voting power of the then outstanding shares of Series D Convertible Preferred Stock (the “Series D Stock”) or Series E Convertible Preferred Stock (the “Series E Stock”) needed to vote in favor of a redemption and provide written notice to the Company at least 60 days prior to the Series E Preferred Stock Redemption Date of such election. The holders of at least a majority in the voting power of the then outstanding shares of the Series A, B and C Convertible Preferred Stock (the “Series C Stock”) could then vote in favor of a redemption, respectively. The holders of at least 66 2/3% of the voting power of the then outstanding shares of Series A Redeemable Convertible Preferred Stock (the “Series A Stock”) could then vote in favor of a Series A Stock redemption. The Series D Stock and Series E Stock redemption value was equal to the Series D Stock and Series E Stock original issue price per share (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like) plus all dividends declared but unpaid thereon together with any accruing dividends accrued but unpaid thereon, whether or not declared with respect to such shares. The Series A/B/C/D and Series E Stock redemption value was equal to the respective series original issue price per share (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like) plus all accrued and unpaid dividends with respect to such shares. If the Company did not have sufficient funds or other assets legally available to redeem all shares to be redeemed at any redemption date, it was to redeem as applicable (i) pro rata to Series E Stock, until all shares were redeemed, (ii) pro rata to Series D Stock until all shares were redeemed, (iii) pro rata to Series C Stock, until all shares were redeemed, (iv) pro rata to Series A Stock and Series B Convertible Preferred Stock (the “Series B Stock”), until all shares were redeemed. If any shares to be redeemed remained outstanding, the Company was to redeem the remaining shares in accordance with the previous sentence as soon as sufficient funds were legally available. Due to the redemption feature, the preferred shares were historically recorded as mezzanine equity. Preferred Shares Carrying Value at 5/11/15 Preferred Shares Before IPO Common Shares After IPO Series A Stock $ 1,403,007 1,292,084 38,973 Series B Stock 2,100,149 6,789,712 75,835 Series C-1 Stock 4,569,063 13,242,612 191,406 Series C-2 Stock 2,225,619 9,948,331 93,757 Series D Stock 30,370,273 140,252,678 1,305,984 Series E Stock 7,879,873 45,989,722 428,237 Carrying value, excluding dividends $ 48,547,984 217,515,139 2,134,192 Series D Stock and Series E Stock cumulative dividends 8,808,065 374,632 Total $ 57,356,049 217,515,139 2,508,824 As of the Company’s IPO in May 2015, Series A Stock, Series B Stock, Series C-1 Stock, Series C-2 Stock, Series D Stock and Series E Stock conversion ratios were 0.030, 0.011, 0.014, 0.009, 0.009 and 0.009, respectively, after consideration of the one-for-107.39 reverse split. When converted at May 11, 2015, all of the outstanding preferred shares and cumulative accrued dividends on Series D Stock and Series E Stock were converted into 2,134,192 and 374,632 shares of Common Stock, respectively. The Company has historically accounted for the Series E Warrants as liabilities as such warrants were indexed to shares that could be redeemed for cash outside the control of the Company. The Company allocated the total proceeds first to the Series E Warrants based on their fair value of approximately $1,890,000 and the remainder amounting to approximately $5,665,000 of the proceeds allocated to the Preferred Shares. The fair value of the Series E Warrants was estimated to approximate the fair value of the Series E Stock because of their nominal price. The amount allocated to the Series E Warrants represented a discount to the Preferred Shares and was being accreted using the effective interest method up to the redemption amount from the respective issuance date to redemption date of five years. Accretion for the three and nine months ended September 30, 2015 was approximately $0 and $128,000, respectively, and accretion for the three and nine months ended September 30, 2014 was approximately $95,000 and $252,000, respectively. Upon immediate exercise of the Series E Warrants, the amount recorded as warrant liability was reclassified to Preferred Shares, and issuance costs of $48,384 which had been allocated to the warrants were expensed. The Company was not accreting to the amount resulting from additional liquidation preference rights under the agreement because they were not considered probable at initial recording or at any point between then and May 2015 IPO. The Company additionally analyzed the issuance of Series E Warrants with the Series E Stock, noting there was no resulting beneficial conversion feature. Following the IPO, all outstanding warrants previously exercisable for Convertible Preferred Stock became exercisable for common stock. The previously reported warrant liability associated with the convertible warrants was applied to additional paid-in-capital. The Company’s Series D Stock and Series E Stock accrued cumulative dividends at 8% per annum on the original issue price of $0.2189, whether or not declared by the Board of Directors. In connection with the Company’s Growth Term Loan, the holders of both the Series D Stock and Series E Stock agreed to waive their rights to cash dividends. As a result, only a share dividend, based on the cumulative dividends divided by the original issue price, could be paid upon declaration by the Board of Directors or upon the automatic conversion of the Convertible Preferred Stock. Dividends were being accreted based on the number of days outstanding. At September 30, 2015 and December 31, 2014, the cumulative Series D Stock and Series E Stock dividends were $ 0 The value of the shares of Series A/B/C/D Stock and Series E Stock was recorded at the amount initially received on the date of issuance or upon conversion from debt, less any applicable discounts for warrants and issuance costs, adjusted for the accretion of discounts utilizing the effective interest method up to the redemption amount from the respective issuance date to the Series E Preferred Stock Redemption Date, and the accretion of cumulative dividends. The redemption value for Series A/B/C Stock agrees to the liquidation value presented on face of the balance sheet. The redemption value of Series D Stock and Series E Stock was $0 at September 30, 2015. On January 30, 2015, 51,681 shares of Series E Convertible Preferred Stock were purchased by a convertible note warrant holder for cash consideration of approximately $7,196.

Stockholders Equity (Deficit)

Stockholders Equity (Deficit)	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Stockholders' Equity (Deficit)	Note 11. Stockholders’ Equity (Deficit) Common Stock The Company amended its certificate of incorporation on May 11, 2015, to decrease the number of authorized shares from 600,000,000 to 200,000,000 shares. The 200,000,000 authorized shares of common stock have a par value of $0.001 per share. As of September 30, 2015, 6,841,260 shares were issued. As of December 31, 2014, 334,003 of the 600,000,000 shares were issued. Each share of common stock is entitled to one vote. All shares of common stock rank equally as to voting and all other matters that the holders are entitled to vote on. The shares of common stock have no preemptive or conversion rights, no redemption or sinking fund provisions, no liability for further call or assessment, and are not entitled to cumulative voting rights. Preferred Stock Pursuant to the Company’s certificate of incorporation the Company has been authorized to issue 10,000,000 shares of preferred stock, each having a par value of $0.001. The preferred stock may be issued from time to time in one or more series with the authorization of the Company’s Board of Directors. The Board of Directors have the ability to determine voting power for each series issued, as well as designation, preferences, and relative, participating, optional or other rights and such qualifications, limitations or restrictions thereof. Stock-based Compensation In February 2014, pursuant to the Series E Agreement, the amount of shares reserved under the Company’s 2011 Equity Incentive Plan (the “2011 Plan”) was increased to 20% of the total outstanding shares of the Company calculated on a fully diluted basis. The shares reserved under the 2011 Plan were required to be kept at that percentage with each subsequent equity financing. No new equity awards may be granted under the 2011 Plan. On May 11, 2015, 940,112 shares were reserved for issuance under the Company’s 2014 Equity Incentive Plan (the “2014 Plan”), including 14,006 shares from the 2011 Plan. As of September 30, 2015, there were 923,031 shares available for issuance under the 2014 Plan. As of September 30, 2015, options to purchase 590,139 shares of common stock were outstanding, including 371,563 options that were fully vested. The remaining options vest over 2.5 years. A summary of the Plans’ stock option activity is as follows: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2014 595,577 $ 3.71 7.8 Granted 17,083 — Exercised (13,764 ) 2.47 $ 92,582 Forfeited (8,757 ) 5.42 Balance at September 30, 2015 590,139 4.01 7.1 5,258,488 Vested and expected to vest at September 30, 2015 580,001 4.01 7.1 5,203,992 Exercisable at September 30, 2015 371,573 3.45 6.3 3,508,953 Below is a summary of stock option grant activity under the 2014 Plan and related fair value information for the nine months ended September 30, 2015: 2015 Grants Options Granted Exercise Price Fair Value of Common Stock on Date of Grant May 5,000 $ 14.64 $ 14.64 June 12,083 $ 13.83 $ 13.83 Total 17,083 Below is a summary of stock option grant activity under the 2011 Plan and related fair value information for the nine months ended September 30, 2014: 2014 Grants Options Granted Exercise Price Fair Value of Common Stock on Date of Grant January 2,094 $ 2.15 $ 2.15 March 249,361 $ 2.15 $ 2.15 May 8,685 $ 2.15 $ 2.15 Total 260,140 The Company issued 27,500 RSUs in the nine months ended September 30, 2015 at a weighted average grant date fair value of $5.45. The RSUs vest 100% on March 31, 2016. As of September 30, 2015, there was total unrecognized compensation expense of $583,701 related to unvested stock options, which the Company expects to recognize over a weighted-average period of approximately 2.5 years. There is an additional $149,875 of unrecognized compensation expense related to RSUs, which will be recognized over the weighted average remaining service period of six months.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 12. Commitments and Contingencies Legal Matters The Company’s industry is characterized by frequent claims and litigation, including claims regarding intellectual property and product liability. As a result, the Company may be subject to various legal proceedings from time to time. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. Any current litigation is considered immaterial and counter claims have been assessed as remote. Severance Agreements and Retention Plans In October 2012, the Board of Directors and 60% of requisite preferred holders approved a plan to set aside no less than 15% of the proceeds of any sale of the Company to be distributed to the Company’s employees, directors or consultants as designated by the Board of Directors (the “HTG Employee Retention Plan”). The HTG Employee Retention Plan terminated pursuant to its terms upon the closing of the IPO. The Company has entered into employment agreements or other arrangements with certain named executive officers and have adopted an Employee Retention Plan for select participants, which provide salary continuation payments, bonuses and, in certain instances, the acceleration of the vesting of certain equity awards to individuals in the event that the individual is terminated other than for cause, as defined in the applicable agreements or arrangements. Indemnification Agreements In the course of operating our business, the Company has entered into, and continues to enter into, separate indemnification agreements with the Company’s directors and executive officers, in addition to the indemnification provided for in the Company’s amended and restated bylaws. These agreements may require the Company to indemnify its directors and executive officers for certain expenses incurred by a director executive officer in any action or proceeding arising out of their services as one of the Company’s directors or executive officers. Leases The Company leases office and laboratory space under two non-cancelable operating leases in Tucson, Arizona, which were set to expire in November and December 2015, respectively, as of September 30, 2015. Under the terms of the two Tucson leases, the Company had one option to extend the leases for five years at the end of the initial seven year lease term. The Company amended its existing facilities leases in August 2015 to extend the terms for five years and to undergo leasehold improvements to expand and improve its existing research, development, operations and administration office facilities. The lease amendment includes an increase of $804,000 in total monthly rent over the remaining life of the lease to compensate the landlord for additional tenant improvements funded by the landlord. In addition to these lease term extensions and increased rents, the Company entered into a construction contract in the third quarter 2015 for the expansion and improvement of its laboratory, manufacturing and office spaces, representing an expected, additional cash outlay commitment by the Company of approximately $500,000 through the first quarter of 2016. As a result of the amendments, the Company’s annual minimum lease payments before common area maintenance charges, which will commence in 2016 and continue through 2020 are as follows: 2016 $ 507,948 2017 510,323 2018 512,734 2019 515,181 2020 517,664 Merck Non-Exclusive License Agreement In June 2012, the Company entered into a non-exclusive license agreement with Merck Sharp & Dohme Cor. (“Merck”) whereby the Company agreed to sublicense certain intellectual property related to breast cancer biomarkers with the intent to develop, manufacture and commercialize a diagnostic test utilizing this technology. The Company agreed to pay Merck certain contingent milestone payments between $50,000 and $1,000,000 and future royalties of 3%-6% of sales derived from such products developed that utilize the licensed technology. No amounts have been accrued or paid under this agreement as the Company has not achieved any of the milestone targets or developed any products that utilize the licensed technology. Product Warranty The following is a summary of the Company’s general product warranty liability for the three months ended September 30, 2015: Warranty reserve, June 30, 2015 $ — Cost of warranty claims (545 ) Warranty accrual 17,225 Warranty reserve, September 30, 2015 $ 16,680 Prior to the three months ended September 30, 2015, no warranty reserves were recorded by the Company.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Note 13. Income Taxes The Company provides for income taxes based upon management’s estimate of taxable income or loss for each respective period. The Company recognizes an asset or liability for the deferred tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. These temporary differences would result in deductible or taxable amounts in future years, when the reported amounts of the assets are recovered or liabilities are settled, respectively. In each period since inception, the Company has recorded a valuation allowance for the full amount of its net deferred tax assets, as the realization of the net deferred tax assets is uncertain. As a result, the Company has not recorded any Federal or state income tax benefit in the statements of operations. The Company periodically reviews its filing positions for all open tax years in all U.S. Federal, state and international jurisdictions where the Company is or might be required to file tax returns or other required reports. The Company applies a two-step approach to recognizing and measuring uncertain tax positions. The Company evaluates the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation process, if any. The term “more likely than not” means a likelihood of more than 50 percent. Otherwise, the Company may not recognize any of the potential tax benefit associated with the position. The Company recognizes a benefit for a tax position that meets the “more likely than not” criterion at the largest amount of tax benefit that is greater than 50 percent likely of being realized upon its effective resolution. Unrecognized tax benefits involve management’s judgment regarding the likelihood of the benefit being sustained. The final resolution of uncertain tax positions could result in adjustments to recorded amounts and may affect the Company’s results of operations, financial position and cash flows. The Company has not identified any uncertain tax positions at September 30, 2015 or December 31, 2014. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties at September 30, 2015 and December 31, 2014, respectively, and has not recognized interest or penalties during the three and nine months ended September 30, 2015 and 2014, respectively, since there are no material unrecognized tax benefits. Management believes no material change to the amount of unrecognized tax benefits will occur within in the next 12 months. The recent IPO could limit the Company’s ability to fully utilize its cumulative net operating losses (“NOL’s”) under Internal Revenue Code Section 382 and similar state provisions. The Company has a full valuation allowance on its NOLs.

Related-Party Transactions

Related-Party Transactions	9 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related-Party Transactions	Note 14. Related-Party Transactions In March 2014 and July 2013, the Company entered into two separate consulting agreements to assess potential markets for its products with a holder of Series D Stock and Series E Stock. The stockholder was paid $0 and $0 for the three and nine months ended September 30, 2015, respectively, and $77,550 and $99,800 for the three and nine months ended September 30, 2014, respectively under those agreements. An employee of the stockholder is a member of the Board of Directors. At September 30, 2015, there were no further amounts due under the consulting agreements.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 15. Subsequent Events On October 29, 2015 the Company completed the development plan milestone of the Illumina, Inc. Agreement (See Note 7). With completion of this milestone, a one-time, non-refundable initial fee of $100,000 will be paid by the Company to Illumina, Inc. and the Company’s Lung Fusion IVD program development process will commence.

Basis of Presentation and Sum24

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying interim unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect the accounts of the Company as of September 30, 2015. Accordingly they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America (“GAAP”) for complete financial statements. The accompanying interim unaudited, condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented. The unaudited condensed balance sheet at December 31, 2014 has been derived from the audited consolidated financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations.
Reverse Stock Split	Reverse Stock Split On April 27, 2015, the Company effected a one-for-107.39 reverse stock split of its outstanding common stock. All applicable common share and per common share information has been retroactively adjusted to reflect the effect of this reverse stock split. The reverse stock split did not change the number of shares of convertible preferred stock outstanding, but did affect the conversion ratios associated with the convertible preferred stock.
Initial Public Offering	Initial On May 11, 2015, the Company successfully completed its initial public offering (“IPO”), in which the Company sold 3,570,000 shares of common stock at $14.00 per share for total gross proceeds of approximately $50 million. An additional 90,076 shares of common stock were subsequently sold pursuant to the partial exercise by the underwriters of their over-allotment option resulting in additional gross proceeds of approximately $1.3 million. After underwriters’ fees and commissions and other expenses of the offering, the Company’s aggregate net proceeds were approximately $45.4 million. All outstanding shares of the Company’s redeemable convertible preferred stock converted into shares of common stock in connection with the IPO. Following the IPO, there were no shares of preferred stock outstanding.
Liquidity	Liquidity The Company expects that the net proceeds from the IPO and its pre-existing cash and cash equivalents, together with interest thereon, will be sufficient to fund its operations for at least the next 12 months. However, the Company has had recurring operating losses and negative cash flows from operations since its inception. As such, the Company expects that it will need to raise additional equity or debt capital at some point in the future until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional equity or debt financing will be available on acceptable terms, or at all, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. The results of operations for the nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the full fiscal year or any other period.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, the value of the warrant liability, the resolution of uncertain tax positions, income tax valuation allowances, recovery of long-lived assets and provisions for doubtful accounts, inventory obsolescence and inventory valuation. Actual results could materially differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash and cash equivalents. Cash and cash equivalents consist of cash on deposit with financial institutions, money market instruments and high credit quality corporate debt securities purchased with a term of three months or less.
Investments	Investments The Company classifies its securities as available-for-sale, which are reported at estimated fair value with unrealized gains and losses included in accumulated other comprehensive income, net of tax. Realized gains, realized losses and declines in value of securities judged to be other-than-temporary, are included in other income (expense). The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Interest and dividends earned on all securities are included in other income (expense). Investments in securities with maturities of less than one year, or where management’s intent is to use the investments to fund current operations, or to make them available for current operations, are classified as short-term investments. If the estimated fair value of a security is below its carrying value, the Company evaluates whether it is more likely than not that it will sell the security before its anticipated recovery in market value and whether evidence indicating that the cost of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. The Company also evaluates whether or not it intends to sell the investment. If the impairment is considered to be other-than-temporary, the security is written down to its estimated fair value. In addition, the Company considers whether credit losses exist for any securities. A credit loss exists if the present value of cash flows expected to be collected is less than the amortized cost basis of the security. Other-than-temporary declines in estimated fair value and credit losses are charged against other income (expense).
Accounts Receivable, net	Accounts Receivable, net Accounts receivable represent valid claims against debtors and have been reported net of an allowance for doubtful accounts of $129,922 and $85,068 at September 30, 2015 and December 31, 2014, respectively. Management reviews accounts receivable to identify where collectability may not be probable based on the specific identification method. Bad debt expense, net of recoveries, was $11,000 and $44,854 for the three and nine months ended September 30, 2015, respectively, and $15,000 and $117,467 for the three and nine months ended September 30, 2014, respectively.
Inventory, net	Inventory, net Inventory, consisting of raw materials and finished goods, is stated at the lower of cost (first-in, first-out) or market. The Company reserves or writes down its inventory for estimated obsolescence, inventory in excess of reasonably expected near term sales or unmarketable inventory, in an amount equal to the difference between the cost of inventory and the estimated market value, based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable. For the three and nine months ended September 30, 2015, the Company recorded an increase in the inventory reserve of $62,872 and $273,752, respectively, to adjust for estimated shrinkage and excess inventory. For the three and nine months ended September 30, 2014, the Company recorded a decrease in the inventory reserve of $536,119 and $536,119, respectively. These amounts were recorded within cost of revenue for each year. During the quarter ended March 31, 2015, the Company determined that the average period of time customers use to evaluate the Company’s equipment generally ranges from 90 to 180 days, and in certain circumstances the evaluation period may need to be extended beyond that period. HTG Edge or HTG EdgeSeq instruments at customer locations under evaluation agreements are included in finished goods inventory. Equipment that is under evaluation for purchase remains in inventory as the Company maintains title to the equipment throughout the evaluation period. If the customer has not completed the purchase of the instrument by the end of the initial evaluation period, the Company will determine whether to extend the evaluation period or have the equipment returned to the Company. However, in no case will the evaluation period exceed one year. If the customer has not purchased the equipment or entered into a reagent agreement with the Company after evaluating for one year, the cost of the equipment is written off to cost of revenue if the customer is allowed to continue use of the equipment. Prior to January 1, 2015, the Company recorded equipment under evaluation more than 90 days in property and equipment. The Company accordingly has reclassified from property and equipment to inventory field equipment with a net book value of $210,606 at December 31, 2014 under evaluation at that time for longer than 90 days and less than one year.
Property and Equipment, net	Property and Equipment, net Property and equipment are stated at historical cost and depreciated over their useful lives, which range from three to five years, using the straight-line method. Leasehold improvements are amortized using the straight-line method over the lesser of the remaining lease term or the estimated useful life. Field equipment is amortized using the straight-line method over the lesser of the period of the related reagent agreement or the estimated useful life. Depreciation and leasehold improvement amortization expense was $174,390 and $473,799 for the three and nine months ended September 30, 2015, respectively, and $120,506 and $349,518 for the three and nine months ended September 30, 2014, respectively. Costs incurred in the development and installation of software for internal use are expensed or capitalized, depending on whether they are incurred in the preliminary project stage (expensed), application development stage (capitalized), or post-implementation stage (expensed). Amounts capitalized following project completion are amortized on a straight-line basis over the useful life of the developed asset, which is generally three years. There was no amortization expense for capitalized software costs for the three and nine months ended September 30, 2015. Amortization expense for capitalized software costs was $3,896 and $15,583 for the three and nine months ended September 30, 2014, respectively.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value. The fair value for securities held is determined using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. The carrying amounts of the Company’s asset-secured growth capital term loan (the “Growth Term Loan”) and convertible notes were estimated using Level 3 inputs and approximate fair value since the interest rate approximates the market rate for debt securities with similar terms and risk characteristics.
Stock Issuance Cost	Stock Issuance Costs Certain costs incurred in connection with the issuance of the Company’s redeemable convertible preferred stock (the “Convertible Preferred Stock”) have been deferred and are being accreted. Stock issuance costs have historically been accreted to distributions in excess of capital using the effective interest method. Accretion was $0 and $35,046 for the three and nine months ended September 30, 2015, respectively, and $19,488 and $71,175 for the three and nine months ended September 30, 2014, respectively. Upon automatic conversion of the Convertible Preferred Stock to common stock in connection with the closing of the Company’s IPO in May 2015, issuance costs were no longer accreted. Stock issuance cost for the three and six months ended June 30, 2014 included in the second quarter 2015 Form 10Q filing was overstated by an immaterial amount of $137,094. This resulted in an overstatement of the net loss per share attributable to common stockholders of $1.42 per share for the three and six months ended June 30, 2014.
Deferred Financing Costs and Debt Discounts	Deferred Financing Costs and Debt Discounts Certain costs incurred in connection with the Growth Term Loan have been deferred and are being amortized. Debt issuance costs and debt discount are amortized over the term of the Growth Term Loan using the effective interest method. In addition, prior to the IPO, costs incurred in connection with the issuance of notes under the Company’s two note and warrant purchase agreements dated December 30, 2014 (the “Note Agreements”) in February and March 2015 were capitalized and amortized over the term of the Note Agreements using the straight-line accretion method, which approximated the effective interest method in this instance. The Company has recorded approximately $59,582 and $75,131 of deferred financing costs in the accompanying condensed balance sheets as of September 30, 2015 and December 31, 2014, respectively. Deferred financing cost amortization expense for the three and nine month periods ended September 30, 2015 was $4,523 and $37,461 respectively. Deferred financing cost amortization was $2,700 for the three and nine months ended September 30, 2014. Amortization of growth term loan discount was $31,595 and $120,627 for the three and nine months ended September 30, 2015, respectively, and is included in interest expense in the accompanying condensed statements of operations. Amortization of the Note Agreement discount was $0 and $90,222 for the three and nine months ended September 30, 2015, respectively, and is included in interest expense in the accompanying condensed statements of operations. The Company compared the value of the common stock issued to settle the debt with the carrying amount of the debt at the IPO closing date of May 2015, net of unamortized discount. The Company recorded a loss on settlement of convertible debt of $705,217, comprised of $651,606 to write off unamortized discount and $53,611 to write off unamortized deferred financing costs relating to the convertible notes which were settled with common stock at the IPO, in the accompanying condensed statements of operations for the three and nine months ended September 30, 2015, respectively. Growth term loan discount accretion was $16,125 for the three and six months ended September 30, 2014, and there was no convertible note discount accretion for the three and nine months ended September 30, 2014.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs represent legal, accounting and other direct costs related to the IPO, which was completed in May 2015. In accounting for the IPO in May 2015, direct offering costs of approximately $2.3 million were reclassified to additional paid-in capital and are shown, along with underwriters’ fees paid, net against IPO proceeds received. The Company recorded $0 and $1.3 million of deferred offering costs as a non-current asset in the accompanying condensed balance sheets as of September 30, 2015 and December 31, 2014, respectively.
Deferred Revenue	Deferred Revenue Deferred revenue represents cash receipts for products or services to be provided in future periods. When products are delivered or services are rendered, deferred revenue is then recognized as earned.
Revenue Recognition	Revenue Recognition The Company recognizes revenue from the sale of instruments, consumables and related services when the following four basic criteria are met: (1) a contract has been entered into with a customer or persuasive evidence of an arrangement exists, (2) delivery has occurred or services rendered, (3) the fee is fixed and determinable, and (4) collectability is reasonably assured. Sale of instruments and consumables Instrument product revenue is generally recognized upon installation and calibration by our field service engineers, unless the customer has specified any other acceptance criteria. The sale of instruments and related installation and calibration are considered to be one unit of accounting, as instruments are required to be professionally installed and calibrated before use. Installation generally occurs within a week of shipment. Consumables are considered to be separate units of accounting as they are sold separately. Consumables revenue is recognized upon transfer of ownership, which is generally upon shipment. The Company’s standard term and conditions provide that no right of return exists for instruments or consumables. Shipping and handling fees charged to the Company’s customers for instruments and consumables shipped are included in the condensed statements of operations as part of product revenue. Shipping and handling costs for sold products shipped to the Company’s customers are included on the condensed statements of operations as part of cost of revenue. When a contract involves multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting. The Company performs this evaluation at the inception of an arrangement and as each item is delivered in the arrangement. Generally, the Company accounts for a deliverable (or a group of deliverables) separately if the delivered item has stand-alone value to the customer, the customer is given a general right of return relative to the delivered item, and delivery or performance of the undelivered item or service is probable and substantially in the Company’s control. When multiple elements can be separated into separate units of accounting, arrangement consideration is allocated at the inception of the arrangement, based on each deliverables’ relative selling price. All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract. The Company provides instruments to certain customers under a reagent agreement. Under these agreements, the Company installs instruments in the customer’s facility without a fee and the customer agrees to purchase consumable products at a stated price over the term of the agreement; in some instances the agreements do not contain a minimum purchase requirement. Terms range from several months to multiple years and may automatically renew in several month or multiple year increments unless either party notifies the other in advance that the agreement will not renew. This represents a multiple element arrangement and because all consideration under the reagent agreement is contingent on the sale of consumables, no consideration has been allocated to the instrument and no revenue has been recognized upon installation of the instrument. The Company expects to recover the cost of the instrument under the agreement through the fees charged for consumables, to the extent sold, over the term of the agreement. Revenue is recognized as consumables are shipped. In reagent rental agreements, the Company retains title to the instrument and title is transferred to the customer at no additional charge at the conclusion of the initial arrangement. Because the pattern of revenue from the arrangement cannot be reasonably estimated, the cost of the instrument is amortized on a straight-line basis over the term of the arrangement, unless there is no minimum consumable product purchase in which case the instrument would be expensed as cost of goods sold. Cost to maintain the instrument while title remains with the Company is charged to cost of revenue as incurred. The Company offers customers the opportunity to purchase separately-priced extended warranty contracts to provide for service upon conclusion of the standard one-year warranty period. The revenue from these contracts is recorded as a component of deferred revenue in the accompanying condensed balance sheets at the inception of the contract and is recognized as revenue over the contract service period. Service Revenue For contracts related to custom panel design services and sample processing, the Company utilizes a proportional performance revenue recognition model, under which revenue is recognized as performance occurs based on the relative outputs of the performance that have occurred up to that point in time under the respective agreement. The Company includes all applicable costs incurred related to custom panel design services, including research and development costs and general and administrative expenses, in cost of revenue. The Company also provides contract research services under cost plus fixed fee government contracts. Revenue is recognized under government contracts using the percentage-of-completion method of accounting. Under the percentage-of-completion method, contract research revenue is recognized as the work progresses and services are rendered and costs are incurred. The fixed fee is recognized in proportion to costs incurred compared to total estimated costs. The Company includes all applicable costs incurred from government contracts, including general and administrative expenses on government contracts, in cost of revenue. Anticipated losses, if any, on contracts are charged to earnings as soon as they are identified. Anticipated losses cover all costs allocable to contracts. Revenue arising from claims or change orders is recorded either as income or as an offset against a potential loss only when the amount of the claim can be estimated and its realization is probable. Other Revenue Other revenue includes license and grant revenue. License revenue is generated from the licensing of the Company’s internally developed intellectual property to third parties. The revenue may be generated by nonrefundable up-front payments and license fees, milestone and other contingent payments, or royalties based on sales of commercialized products. Licensing fees are recognized on a straight-line basis over the term of the license agreement for agreements requiring specific continuing performance obligations with deferral of all or a portion of these fees. If it cannot be concluded that a license fee is fixed or determinable at the outset of an arrangement, amounts are recognized as income as payments from third parties become due. No licensing fees were included in other revenue for the three and nine months ended September 30, 2015 and 2014. Grant revenue is earned when expenditures relating to the projects under these awards are incurred.
Product Warranty	Product Warranty The Company generally provides a one-year warranty on its HTG Edge and HTG EdgeSeq systems covering the performance of system hardware and software in conformance with customer specifications under normal use and protecting against defects in materials and workmanship. The Company may, at its option, replace, repair or exchange products covered under valid warranty claims. A provision for estimated warranty costs is recognized at the time of sale, through Cost of Revenue, based upon recent historical experience and other relevant information as it becomes available. The Company continuously assesses the adequacy of its product warranty accrual by reviewing actual claims and makes adjustments to the provision as needed. Due to a lack of historical data and a low rate of warranty claims, the Company had not recorded any liability for product warranty prior to the current period. Note 12 “Commitments and Contingencies” contains additional information relating to the Company’s product warranties.
Research and Development Expenses	Research and Development Expenses Research and development expenses represent both costs incurred internally for research and development activities and costs incurred externally to fund research activities. All research and development costs are expensed as incurred. During the quarter ended September 30, 2015, the Company entered into a Development and Professional Services agreement with Invetech PTY Ltd. (Note 7) for the development of its low volume throughput HTG EdgeSeq platform, for which $150,000 of research and development expense was recorded for the three and nine months ended September 30, 2015.
Stock-Based Compensation	Share-Based Compensation The Company recognizes expense for share-based payments to employees, including grants of stock options and restricted stock units, based on the fair value of awards on the date of grant. The fair value of each employee stock option granted pursuant to the Company’s equity incentive plans is estimated on the date of grant using the Black-Scholes option pricing model. The determination of the fair value of share-based payment awards utilizing the Black-Scholes option pricing model is affected by the fair value of the Company’s stock price and a number of assumptions, including volatility, expected term, risk-free interest rate, and dividend yield. Generally these assumptions are based on historical information and judgment is required to determine if historical trends may be indicators of future outcomes. Employee stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates and an adjustment to stock-based compensation expense will be recognized at that time. Changes to assumptions used in Black-Scholes option valuation calculation and the forfeiture rate could significantly impact the compensation expense recognized by the Company. The Company uses fair value to account for restricted stock units (RSUs). The RSUs are valued based on the quoted market price of common stock on the date of grant and amortized ratably over the life of the award. For share-based payments to nonemployee consultants, the fair value of the share-based consideration issued is used to measure the transaction, as the Company believes this to be a more reliable measure of fair value than the services received. The fair value of the award is measured at the fair value of the Company’s stock options on the date that the commitment for performance by the nonemployee consultant has been reached or performance is complete. Stock-based compensation costs are recognized as expense over the requisite service period, which is generally the vesting period for awards, on a straight-line basis.
Concentration Risks	Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and uncollateralized accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The Company sells its instruments, consumables, sample processing services, custom panel design services and contract research services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The top three customers accounted for 26%, 16% and 12% of the Company’s revenue for the three months ended September 30, 2015, compared with 19%, 19% and 5% for the three months ended September 30, 2014. The largest two customers accounted for 29% and 10% of the Company’s revenue for the nine months ended September 30, 2015. The largest three customers accounted for 12%, 10% and 9% for the nine months ended September 30, 2014. The Company derived 0% and 12% of its total revenue from grants and contracts, primarily from one organization during the three and nine month periods ended September 30, 2015, respectively. 27% and 32% of total revenue was derived from grants and contracts primarily from one organization, during the three and nine month periods ended September 30, 2014, respectively. The largest two customers accounted for approximately 23% and 23% of the Company’s net accounts receivable as of September 30, 2015. One customer accounted for approximately 31% of the Company’s net accounts receivable at December 31, 2014. The Company currently relies on a single vendor to manufacture its HTG Edge processor and reader and HTG EdgeSeq processor and additional single suppliers to supply subcomponents used in the processor. A loss of any of these suppliers could significantly delay the delivery of HTG Edge systems, which in turn would materially affect the Company’s ability to generate revenue.
New Accounting Pronouncements	New Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing GAAP. The revised revenue standard is effective for public entities for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of our pending adoption of ASU 2014-09 on our financial statements and has not yet determined the method by which we will adopt the standard. In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Going Concern (“ASU 2014-15”). ASU 2014-15 provides GAAP guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The standard will be effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company does not believe the adoption of this standard will have a significant impact on the Company’s financial statements. In April 2015, the FASB issued Accounting Standards Update No. 2015-03, Interest – Imputation of Interest: Simplifying the presentation of Debt Issuance Costs (“ASU 2015-03”). The standard requires entities to present debt issuance costs on the balance sheet as a direct deduction from the related debt liability rather than as an asset, and the amortization is reported as interest expense. The result of application of this guidance would be to reduce the deferred financing costs balance, with a corresponding reduction to the long term liabilities to which the debt issuance costs relate in the condensed balance sheets. The standard does not affect recognition and measurement of debt issuance costs. The Company expects to adopt ASU 2015-03 on January 1, 2016. In July 2015, the FASB issued Accounting Standards Update 2015-11, Inventory: Simplifying the Measurement of Inventory (“ASU 2015-11”). The standard requires inventory within the scope of the ASU to be measured using the lower of cost and net realizable value. The changes apply to all types of inventory, except those measured using LIFO or retail inventory method, and are intended to more clearly articulate the requirements for the measurement and disclosure of inventory and to simplify the accounting for inventory by eliminating the notions of replacement cost and net realizable value less a normal profit margin. The standard will be effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. The Company does not believe the adoption of this standard will have a significant impact on the Company’s financial statements.

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory, net of allowance, consisted of the following as of the date indicated: September 30, December 31, 2015 2014 Raw materials $ 971,118 $ 1,029,927 Work in process 22 — Finished goods 1,295,042 655,887 $ 2,266,182 $ 1,685,814

Fair Value of Financial Instr26

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table classifies the Company’s financial assets and liabilities measured at fair value on a recurring basis at September 30, 2015 and December 31, 2014, respectively into the fair value hierarchy: Balance at September 30, 2015 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 2,573,882 $ — $ — $ 2,573,882 Investments at fair value U.S. government obligations $ 3,308,573 $ — $ — $ 3,308,573 U.S. government agency obligations $ — $ 14,715,616 $ — $ 14,715,616 Corporate debt securities $ — $ 18,454,522 $ — $ 18,454,522 Balance at December 31, 2014 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 3,608,890 $ — $ 3,608,890 Liabilities included in: Growth Term Loan warrants $ — $ — $ 301,508 $ 301,508 Convertible Preferred Stock warrants $ — $ — $ 429,035 $ 429,035
Summary of Fair Value Assessment of Warrant Liability Inputs using Black Sholes Option Pricing Model	The December 31, 2014 fair value assessments used the Black-Sholes option pricing model using the following assumptions: December 31, 2014 Fair value of Series B/C/D Stock and Series E Stock shares on grant date or measurement date $0.14 - $0.22 Exercise price $0.01 - $0.346 Expected risk-free interest rate 1.20% Expected volatility 70% Expected term 4.1 years Expected dividend yield 0 - 8%
Reconciliation of Beginning and Ending Liabilities Measured at Fair Value on Recurring Basis	A reconciliation of the beginning and ending liabilities measured at fair value and classified as Level 3 inputs for the nine months ended September 30, 2015 and September 30, 2014 are as follows: September 30, 2015 2014 Beginning balance $ 730,543 $ 44,120 Issuance of Series E Convertible Preferred Stock Warrants — 2,191,507 Exercise of Series E Convertible Preferred Stock Warrants (4,116 ) (1,890,000 ) Exercise of Series D Convertible Preferred Stock Warrants (91,798 ) — Reclassification of Series C-2 Convertible Preferred Stock Warrants to Common Stock Warrants (555 ) — Reclassification of Growth Term Loan Warrants to Common Warrants (229,550 ) — Issuance of Convertible Note Warrants 741,828 — Reclassification of Convertible Note Warrants to Common Stock Warrants (1,386,035 ) — Change in Convertible Preferred Stock warrant valuation 239,683 56,322 Ending balance $ — $ 401,949

Available for Sale Securities (

Available for Sale Securities (Tables)	9 Months Ended
	Sep. 30, 2015
Investments Debt And Equity Securities [Abstract]
Summary of Available-for-sale Securities	The following is a summary of the Company’s available-for-sale securities at September 30, 2015: Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) US Treasury securities and obligations of US government agencies $ 18,015,477 $ 8,712 $ — $ 18,024,189 Corporate securities 18,458,480 1,179 (5,137 ) 18,454,522 Total available-for-sale securities $ 36,473,957 $ 9,891 $ (5,137 ) $ 36,478,711
Summary of Contractual Maturities of Debt Investment Securities	Contractual maturities of debt investment securities at September 30, 2015, are shown below. Under 1 Year 1 to 2 Years Total US Treasury securities and obligations of US government agencies $ 13,085,633 $ 4,938,556 $ 18,024,189 Corporate securities 15,626,126 2,828,396 18,454,522 Total available-for-sale securities $ 28,711,759 $ 7,766,952 $ 36,478,711
Summary of Debt Securities with Unrealized Losses	The following tables shows the gross unrealized losses and fair values of the Company’s investments that have unrealized losses, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position as of September 30, 2015: Under 1 Year 1 to 2 Years Total Gross Gross Gross Fair Unrealized Fair Unrealized Fair Unrealized Value Losses Value Losses Value Losses Corporate securities $ 3,430,702 $ 5,137 $ — $ — $ 3,430,702 $ 5,137 Total available-for-sale securities with unrealized losses $ 3,430,702 $ 5,137 $ — $ — $ 3,430,702 $ 5,137

Debt Obligations (Tables)

Debt Obligations (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Principal Repayments Due Under Term Loan	The principal repayments due under the term loan as of September 30, 2015, are as follows: 2015 $ — 2016 3,059,068 2017 4,393,103 2018 3,547,829 Total Growth Term Loan payments 11,000,000 Less discount (416,204 ) Plus final fee premium 172,599 Total Growth Term Loan, net $ 10,756,395

Other Agreements (Tables)

Other Agreements (Tables)	9 Months Ended
	Sep. 30, 2015
Commitments And Contingencies Disclosure [Abstract]
Schedule of Remaining Payments Due	The remaining payments due to NuvoGen at September 30, 2015, are as follows: 2015 $ — 2016 543,750 2017 800,000 2018 400,000 2019 400,000 2020 and beyond 7,098,743 Total NuvoGen obligation payments 9,242,493 Less discount (335,402 ) Total NuvoGen obligation, net $ 8,907,091

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Reconciliation of Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share	The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share for the periods presented: Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Numerator: Net loss $ (5,157,663 ) $ (3,307,329 ) $ (15,698,139 ) $ (9,819,746 ) Accretion of stock issuance costs — (19,488 ) (35,046 ) (71,175 ) Accretion of discount on Series E warrants — (94,893 ) (127,616 ) (251,893 ) Series E and D, Convertible Preferred Stock dividends — (837,225 ) (1,165,932 ) (2,405,987 ) Net loss attributable to common stockholders $ (5,157,663 ) $ (4,258,935 ) $ (17,026,733 ) $ (12,548,801 ) Denominator: Weighted-average common shares outstanding -basic and diluted 6,829,687 96,486 3,735,852 96,446 Net loss per share attributable to common stockholders, basic and diluted $ (0.76 ) $ (44.14 ) $ (4.56 ) $ (130.11 )
Outstanding Options, Warrants and Convertible Preferred Stock Excluded from Computation of Diluted Net Loss per Share	The following outstanding options, warrants and Convertible Preferred Stock were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Three and Nine Months Ended September 30, 2015 2014 Options to purchase common stock 590,139 542,435 Restricted stock units 27,500 — Convertible Preferred Stock (as converted) — 2,353,166 Convertible Preferred Stock warrants (as converted) — 51,863 Common stock warrant 170,587 931

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2015
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Summary of Outstanding Warrants	Security Number of Preferred and Common Warrants at December 31, 2014 Number of Common Warrants at September 30, 2015 Exercise Price/Share Expiration Date Series C-1 redeemable convertible preferred stock warrants 1,290,350 — $ 37.16 2016-2017 Series C-2 redeemable convertible preferred stock warrants 157,912 1,488 24.23 2015 Series D redeemable convertible preferred stock warrants 769,059 — 1.07 2020 Series E redeemable convertible preferred stock warrants 2,512,562 23,396 23.51 2024 Convertible note warrants — 144,772 14.00 2022 Common stock warrants 931 931 6.45 2019

Redeemable Convertible Prefer32

Redeemable Convertible Preferred Stock (Tables)	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Summary of Preferred Stock	Preferred Shares Carrying Value at 5/11/15 Preferred Shares Before IPO Common Shares After IPO Series A Stock $ 1,403,007 1,292,084 38,973 Series B Stock 2,100,149 6,789,712 75,835 Series C-1 Stock 4,569,063 13,242,612 191,406 Series C-2 Stock 2,225,619 9,948,331 93,757 Series D Stock 30,370,273 140,252,678 1,305,984 Series E Stock 7,879,873 45,989,722 428,237 Carrying value, excluding dividends $ 48,547,984 217,515,139 2,134,192 Series D Stock and Series E Stock cumulative dividends 8,808,065 374,632 Total $ 57,356,049 217,515,139 2,508,824

Stockholders Equity (Deficit) (

Stockholders Equity (Deficit) (Tables)	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Summary of Stock Option Plans Activity	A summary of the Plans’ stock option activity is as follows: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2014 595,577 $ 3.71 7.8 Granted 17,083 — Exercised (13,764 ) 2.47 $ 92,582 Forfeited (8,757 ) 5.42 Balance at September 30, 2015 590,139 4.01 7.1 5,258,488 Vested and expected to vest at September 30, 2015 580,001 4.01 7.1 5,203,992 Exercisable at September 30, 2015 371,573 3.45 6.3 3,508,953
Summary of Stock Option Grant Activity and Fair Value Information	Below is a summary of stock option grant activity under the 2014 Plan and related fair value information for the nine months ended September 30, 2015: 2015 Grants Options Granted Exercise Price Fair Value of Common Stock on Date of Grant May 5,000 $ 14.64 $ 14.64 June 12,083 $ 13.83 $ 13.83 Total 17,083 Below is a summary of stock option grant activity under the 2011 Plan and related fair value information for the nine months ended September 30, 2014: 2014 Grants Options Granted Exercise Price Fair Value of Common Stock on Date of Grant January 2,094 $ 2.15 $ 2.15 March 249,361 $ 2.15 $ 2.15 May 8,685 $ 2.15 $ 2.15 Total 260,140

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2015
Commitments And Contingencies Disclosure [Abstract]
Minimum Lease Payments Before Common Area Maintenance Charges	As a result of the amendments, the Company’s annual minimum lease payments before common area maintenance charges, which will commence in 2016 and continue through 2020 are as follows: 2016 $ 507,948 2017 510,323 2018 512,734 2019 515,181 2020 517,664
Summary of Product Warranty Liability	The following is a summary of the Company’s general product warranty liability for the three months ended September 30, 2015: Warranty reserve, June 30, 2015 $ — Cost of warranty claims (545 ) Warranty accrual 17,225 Warranty reserve, September 30, 2015 $ 16,680

Description of Business - Addit

Description of Business - Additional Information (Details) - Segment	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Significant Accounting Policies [Line Items]
Number of operating segments			1
Sales Revenue, Net | Customer Concentration Risk | Customers Located Outside Of United States
Significant Accounting Policies [Line Items]
Sales revenue percentage	24.00%	7.00%	11.00%	18.00%

Basis of Presentation and Sum36

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)	May. 11, 2015USD ($)$ / sharesshares	Apr. 27, 2015	May. 31, 2015USD ($)	Sep. 30, 2015USD ($)Customershares	Sep. 30, 2014USD ($)Customer	Jun. 30, 2014USD ($)$ / shares	Sep. 30, 2014USD ($)	Jun. 30, 2014USD ($)$ / shares	Sep. 30, 2015USD ($)Customershares	Sep. 30, 2014USD ($)Customer	Dec. 31, 2014USD ($)Customershares
Significant Accounting Policies [Line Items]
Reverse stock split of outstanding common stock		0.0093
Common stock, at the initial public offering price per shares | $ / shares	$ 14
Gross proceeds from initial public offering									$ 47,654,190
Preferred stock, shares outstanding | shares				0					0		0
Maturity period of investments									less than one year
Allowance for Doubtful Accounts Receivable				$ 129,922					$ 129,922		$ 85,068
Bad debt expense, net of recoveries				11,000	$ 15,000				44,854	$ 117,467
Change in inventory valuation reserves				62,872	(536,119)				273,752	(536,119)
Reclassified equipment with a net book value											210,606
Depreciation and leasehold improvement amortization expense				174,390	120,506				473,799	349,518
Amortization expense for capitalized software costs				0	3,896				0	15,583
Accretion of preferred stock issuance costs				0	19,488				35,046	71,175
Overstated stock issuance cost immaterial amount						$ 137,094		$ 137,094
Overstated net loss per share attributable to common stockholders | $ / shares						$ 1.42		$ 1.42
Deferred financing costs				59,582					59,582		75,131
Deferred financing cost amortization expense				4,523	2,700				37,461	2,700
Debt instrument, amortization expense				51,481	46,867				229,232	141,551
Amortization of discount on convertible notes				0					90,222
Loss on settlement of convertible notes									705,217
Accretion of discount on NuvoGen obligation									229,232	141,551
Write off of deferred financing costs									53,611
Write off unamortized debt discount									651,606
Deferred offering costs, noncurrent				0					0		$ 1,300,000
Licenses revenue fees				0	0				0	0
Research and development				$ 1,309,573	$ 649,949				$ 2,951,009	$ 2,372,972
Sales Revenue, Net | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer				3	3				2	3
Sales Revenue, Net | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage				26.00%	19.00%				29.00%	12.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage				16.00%	19.00%				10.00%	10.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Three
Significant Accounting Policies [Line Items]
Sales revenue percentage				12.00%	5.00%					9.00%
Accounts Receivable | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer									2		1
Accounts Receivable | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage									23.00%		31.00%
Accounts Receivable | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage									23.00%
Revenue from grants and contracts | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Sales revenue percentage				0.00%	27.00%				12.00%	32.00%
Invetech PTY Ltd. Agreement
Significant Accounting Policies [Line Items]
Research and development				$ 150,000					$ 150,000
Growth Term Loan A
Significant Accounting Policies [Line Items]
Debt instrument, amortization expense				$ 31,595	$ 16,125				$ 120,627	$ 16,125
Accretion of discount on NuvoGen obligation					16,125		$ 16,125
Convertible Notes
Significant Accounting Policies [Line Items]
Accretion of discount on NuvoGen obligation					$ 0					$ 0
Software and Software Development Costs
Significant Accounting Policies [Line Items]
Long-term asset, estimated life									3 years
Minimum
Significant Accounting Policies [Line Items]
Long-term asset, estimated life									3 years
Maximum
Significant Accounting Policies [Line Items]
Long-term asset, estimated life									5 years
IPO
Significant Accounting Policies [Line Items]
Issuance of common stock from initial public offering, shares | shares	3,570,000
Common stock, at the initial public offering price per shares | $ / shares	$ 14
Gross proceeds from initial public offering	$ 50,000,000
Net proceeds from initial public offering after underwriters' fees, commissions and offering costs	$ 45,400,000
Preferred stock, shares outstanding | shares				0					0
Reclassification of additional paid in capital with direct offering costs			$ 2,300,000
Over-Allotment Option
Significant Accounting Policies [Line Items]
Issuance of common stock from initial public offering, shares | shares	90,076
Proceeds from issuance of common stock	$ 1,300,000

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 971,118	$ 1,029,927
Work in process	22
Finished goods	1,295,042	655,887
Inventory, net	$ 2,266,182	$ 1,685,814

Fair Value of Financial Instr38

Fair Value of Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Cash and Cash Equivalents | Money Market Securities
Asset included in:
Financial Assets	$ 2,573,882	$ 3,608,890
Investments at Fair Value | US Government Obligations
Asset included in:
Financial Assets	3,308,573
Investments at Fair Value | US Government Agency Obligations
Asset included in:
Financial Assets	14,715,616
Investments at Fair Value | Corporate Debt Securities
Asset included in:
Financial Assets	18,454,522
Convertible Preferred Stock Warrants
Liabilities included in:
Financial Liabilities		429,035
Warrant
Liabilities included in:
Financial Liabilities		301,508
Level 1 | Cash and Cash Equivalents | Money Market Securities
Asset included in:
Financial Assets	2,573,882	3,608,890
Level 1 | Investments at Fair Value | US Government Obligations
Asset included in:
Financial Assets	3,308,573
Level 2 | Investments at Fair Value | US Government Agency Obligations
Asset included in:
Financial Assets	14,715,616
Level 2 | Investments at Fair Value | Corporate Debt Securities
Asset included in:
Financial Assets	$ 18,454,522
Level 3 | Convertible Preferred Stock Warrants
Liabilities included in:
Financial Liabilities		429,035
Level 3 | Warrant
Liabilities included in:
Financial Liabilities		$ 301,508

Fair Value of Financial Instr39

Fair Value of Financial Instruments - Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair value assets, Level 1 to Level 2 transfers, Amount	$ 0	$ 0	$ 0
Fair value, assets, Level 2 to Level 1 transfers, Amount	0	0	0
Fair value, liabilities, Level 1 to Level 2 transfers, Amount	0	0	0
Fair value, liabilities, Level 2 to Level 1 transfers, Amount	0	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into Level 3	0	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring Basis, asset, transfers out of Level 3	0	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers into Level 3	0	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers out of Level 3	$ 0	$ 0	$ 0
Class of Warrant or Right, Outstanding	0	0

Fair Value of Financial Instr40

Fair Value of Financial Instruments - Summary of Fair Value Assessment of Warrant Liability Inputs using Black Sholes Option Pricing Model (Details)	3 Months Ended	12 Months Ended
	Dec. 31, 2014$ / shares	Dec. 31, 2014$ / shares
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value of Series B/C/D Stock and Series E Stock shares on grant date or measurement date	$ 0.13	$ 0.13
Expected risk-free interest rate	1.60%	1.20%
Expected volatility	75.00%	70.00%
Expected term	7 years	4 years 1 month 6 days
Expected dividend yield	0.00%
Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value of Series B/C/D Stock and Series E Stock shares on grant date or measurement date	$ 0.14	$ 0.14
Exercise price	0.01	$ 0.01
Expected dividend yield		0.00%
Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair value of Series B/C/D Stock and Series E Stock shares on grant date or measurement date	0.22	$ 0.22
Exercise price	$ 0.346	$ 0.346
Expected dividend yield		8.00%

Fair Value of Financial Instr41

Fair Value of Financial Instruments - Reconciliation of Beginning and Ending Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 730,543	$ 44,120
Issuance of warrants	741,828
Change in convertible preferred stock warrant valuation	239,683	56,322
Ending balance		401,949
Series E Convertible Preferred Stock Warrants
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Issuance of warrants		2,191,507
Exercise of warrants	(4,116)	$ (1,890,000)
Series D Convertible Preferred Stock Warrants
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Exercise of warrants	(91,798)
Convertible Note Warrants
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Reclassification of warrants	(1,386,035)
Series C-2 Convertible Preferred Stock Warrants
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Reclassification of warrants	(555)
Growth Term Loan
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Reclassification of warrants	$ (229,550)

Available for Sale Securities -

Available for Sale Securities - Summary of Available for Sale Securities (Details)	9 Months Ended
	Sep. 30, 2015USD ($)
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 36,473,957
Gross Unrealized Gains	9,891
Gross Unrealized Losses	(5,137)
Fair Value (Net Carrying Amount)	36,478,711
US Treasury Securities and Obligations of US Government Agencies
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	18,015,477
Gross Unrealized Gains	8,712
Fair Value (Net Carrying Amount)	18,024,189
Corporate Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	18,458,480
Gross Unrealized Gains	1,179
Gross Unrealized Losses	(5,137)
Fair Value (Net Carrying Amount)	$ 18,454,522

Available for Sale Securities43

Available for Sale Securities - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Schedule Of Available For Sale Securities [Line Items]
Net unrealized holding gains (losses)	$ 4,754	$ 0
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Other-than-temporary impairment	$ 0

Available for Sale Securities44

Available for Sale Securities - Summary of Contractual Maturities of Debt Investment Securities (Details)	Sep. 30, 2015USD ($)
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	$ 28,711,759
1 to 2 Years	7,766,952
Fair Value (Net Carrying Amount)	36,478,711
US Treasury Securities and Obligations of US Government Agencies
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	13,085,633
1 to 2 Years	4,938,556
Fair Value (Net Carrying Amount)	18,024,189
Corporate Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	15,626,126
1 to 2 Years	2,828,396
Fair Value (Net Carrying Amount)	$ 18,454,522

Available for Sale Securities45

Available for Sale Securities - Summary of Debt Securities with Unrealized Losses (Details)	Sep. 30, 2015USD ($)
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year, Fair Value	$ 3,430,702
Under 1 Year, Gross Unrealized Losses	5,137
Total, Fair Value	3,430,702
Total, Gross Unrealized Losses	5,137
Corporate Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year, Fair Value	3,430,702
Under 1 Year, Gross Unrealized Losses	5,137
Total, Fair Value	3,430,702
Total, Gross Unrealized Losses	$ 5,137

Debt Obligations - Additional I

Debt Obligations - Additional Information (Details)	Dec. 30, 2014USD ($)AgreementFuture$ / sharesshares	May. 31, 2015USD ($)$ / sharesshares	Aug. 31, 2014USD ($)Institution$ / sharesshares	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Aug. 31, 2015	Dec. 31, 2014USD ($)	Aug. 22, 2014USD ($)
Debt Obligations [Line Items]
Debt instrument, amortization expense				$ 51,481	$ 46,867	$ 229,232	$ 141,551
Financing costs						75,523
Number of convertible promissory note agreements | Agreement	2
Issuance of common stock from initial public offering						45,354,186
Investor equity with warrants percentage	80.00%
Outstanding convertible notes payable	$ 0
Fair value of warrants									$ 741,828
Conversion of stock, amount converted						4,544,384
Percentage of possible outcomes in debt note agreements issued		50.00%
Write off unamortized debt discount and deferred financing costs				705,217		705,217
Convertible Debt
Debt Obligations [Line Items]
Amortization of warrant discount				0	0	90,222	0
Series E Convertible Preferred Stock
Debt Obligations [Line Items]
Class of warrant or right per share price | $ / shares	$ 0.2189
Growth Term Loan
Debt Obligations [Line Items]
Number of loan lending institutions | Institution			2
Final Payment Percentage								4.75%
Financing costs			$ 100,000
Growth Term Loan | Scenario Forecast One
Debt Obligations [Line Items]
prepayment fee Percentage								3.00%
Growth Term Loan | Scenario Forecast Two
Debt Obligations [Line Items]
prepayment fee Percentage								2.00%
Growth Term Loan | Scenario Forecast Three
Debt Obligations [Line Items]
prepayment fee Percentage								1.00%
Growth Term Loan | Series E Stock
Debt Obligations [Line Items]
Financial institution warrant issued, share | shares			2,512,562
Class of warrant or right per share price | $ / shares			$ 0.2189
Warrants expiration date			Aug. 22, 2024
Growth Term Loan A
Debt Obligations [Line Items]
Term loan payable										$ 11,000,000
Debt instrument, amortization expense				31,595	$ 16,125	$ 120,627	$ 16,125
Debt instrument, fixed rate			8.50%
Monthly periodic payment			$ 408,296
Growth Term Loan A | Maximum
Debt Obligations [Line Items]
Debt instrument, maturity date						Sep. 30, 2018
Growth Term Loan A | Minimum
Debt Obligations [Line Items]
Debt instrument, maturity date						Sep. 30, 2015
Growth Term Loan B
Debt Obligations [Line Items]
Term loan payable			5,000,000
Debt issuance costs			$ 300,000
Convertible Notes
Debt Obligations [Line Items]
Debt conversion, converted instrument, rate	80.00%
Extinguishment of debt as percentage of principal amount	80.00%
Debt Instrument, Convertible, Terms of Conversion Feature						Under each of the Note Agreements, the failure of a principal or major participating investor to invest their committed amount at each of the closings resulted in the conversion of a percentage of the investor’s preferred shares into common shares at the applicable conversion rates in effect pursuant to the Company’s restated certificate of incorporation. Under the first Note Agreement, failure of a principal investor to purchase their committed amount resulted in the conversion of their entire holdings of Convertible Preferred Stock into common stock, at conversion rates then in effect. Under the second Note Agreement, up to 80% of the total Convertible Preferred Stock held by such investor will be converted into common stock, at conversion rates then in effect. In addition, failure to purchase the full committed amount in any closing will result in the termination of the applicable investor’s warrants, in whole or in part, and the forgiveness and extinguishment of 80% of the aggregate principal amount of the applicable investor’s outstanding notes, if any. In the event the Company sold new shares of stock in a qualified initial public offering or preferred stock in a private placement, an investor’s failure to participate in the subsequent equity financing, in an amount equal to their applicable remaining committed amount under the Note Agreements, would result in the conversion of up to 80% of the non-participating investor’s aggregate Convertible Preferred Stock holding as of the closing date of the subsequent equity financing, along with a reduction of up to 80% of the non-participating investor’s warrants. Pursuant to the provisions of the second Note Agreement, certain preferred shares were optionally converted into common stock as of December 30, 2014.
Fair value of warrants				$ 741,828		$ 741,828
Settlement of outstanding principal and accrued interest on convertible notes by issuance of common stock, shares | shares		324,591
Conversion price per share | $ / shares		$ 14
Conversion of stock, amount converted		$ 4,500,000
Convertible Notes | Minimum | Private Placement
Debt Obligations [Line Items]
Proceeds from sale of preferred stock, net of issuance costs	$ 20,000,000
Convertible Note One
Debt Obligations [Line Items]
Debt instrument, fixed rate	8.00%
Debt instrument, maturity date						Mar. 31, 2016
Issuance of common stock from initial public offering	$ 7,339,165
Number of future issued to existing investors | Future	5
Closing value	$ 1,500,000
Number of days of notice to participating investors	10 days
Convertible note draws		4,500,000
Convertible Note One | Series E Convertible Preferred Stock
Debt Obligations [Line Items]
Financial institution warrant issued, share | shares	5,029,114
Class of warrant or right per share price | $ / shares	$ 0.2189
Convertible Note Two
Debt Obligations [Line Items]
Debt instrument, fixed rate	8.00%
Debt instrument, maturity date						Mar. 31, 2016
Issuance of common stock from initial public offering	$ 6,203,971
Number of future issued to existing investors | Future	4
Closing value	$ 1,703,971
Number of days of notice to participating investors	10 days
Conversion percentage	80.00%
Convertible note draws		$ 0
Convertible Note Two | Series E Convertible Preferred Stock
Debt Obligations [Line Items]
Financial institution warrant issued, share | shares	4,282,472
Class of warrant or right per share price | $ / shares	$ 0.2189

Debt Obligations - Principal Re

Debt Obligations - Principal Repayments Due Under Term Loan (Details) - Term Loan	Sep. 30, 2015USD ($)
Debt Instrument [Line Items]
2,016	$ 3,059,068
2,017	4,393,103
2,018	3,547,829
Total Growth Term Loan payments	11,000,000
Less discount	(416,204)
Plus final fee premium	172,599
Total Growth Term Loan, net	$ 10,756,395

Other Agreements - Additional I

Other Agreements - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Other Agreements [Line Items]
Upfront consideration paid in exchange of common stock			600,000
Remaining cash consideration to be paid	$ 15,000,000		$ 15,000,000
Percentage on annual revenues for cash consideration to be paid			6.00%
Discount rate used to calculate asset purchase obligation			2.50%
Payments on obligation	0	$ 981,250	$ 0	$ 1,206,250
Accretion of discount on NuvoGen obligation	51,481	46,867	229,232	141,551
Research and development	1,309,573	$ 649,949	$ 2,951,009	$ 2,372,972
Agreement expiration date			Oct. 31, 2019
Description on termination of agreement			The Company may terminate the agreement at any time upon 90 days’ written notice and may terminate any development plan under the agreement upon 30 days’ prior written notice. Illumina may terminate the agreement upon 30 days’ prior written notice if the Company undergoes certain changes of control or immediately if the Company fails to select a testing field for an IVD test kit within 24 months following the date of the agreement. Either party may terminate the agreement upon the other party’s material breach of the agreement that remains uncured for 30 days, or upon the other party’s bankruptcy
Illumina, Inc. Agreement
Other Agreements [Line Items]
Aggregate payment upon achievement of specified regulatory milestones	1,000,000		$ 1,000,000
Research and development			0
Invetech PTY Ltd. Agreement
Other Agreements [Line Items]
Research and development	150,000		150,000
Growth Term Loan
Other Agreements [Line Items]
Minimum payments of pledged intangible assets due in 2014	868,750		868,750
Minimum payments of pledged intangible assets due in 2015	868,750		868,750
Minimum payments of pledged intangible assets due in first quarter of 2016	868,750		868,750
Minimum payments of pledged intangible assets due in second quarter of 2016	0		0
NuvoGen
Other Agreements [Line Items]
Convertible notes and related debt discount	$ 335,402		$ 335,402		$ 564,634

Other Agreements - Schedule of

Other Agreements - Schedule of Remaining Payments Due (Details) - NuvoGen Asset Purchase Agreement	Sep. 30, 2015USD ($)
Purchase Obligation Fiscal Year Maturity [Line Items]
2,015	$ 0
2,016	543,750
2,017	800,000
2,018	400,000
2,019	400,000
2020 and beyond	7,098,743
Total NuvoGen obligation payments	9,242,493
Less discount	(335,402)
Total NuvoGen obligation, net	$ 8,907,091

Net Loss per Share - Reconcilia

Net Loss per Share - Reconciliation of Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Numerator:
Net loss	$ (5,157,663)	$ (3,307,329)	$ (15,698,139)	$ (9,819,746)
Accretion of stock issuance costs	0	(19,488)	(35,046)	(71,175)
Accretion of Series D and E redeemable convertible preferred stock dividends		(837,225)	(1,165,932)	(2,405,987)
Net loss attributable to common stockholders	$ (5,157,663)	$ (4,258,935)	$ (17,026,733)	$ (12,548,801)
Denominator:
Weighted-average common shares outstanding -basic and diluted	6,829,687	96,486	3,735,852	96,446
Net loss per share attributable to common stockholders, basic and diluted	$ (0.76)	$ (44.14)	$ (4.56)	$ (130.11)
Series E Warrants
Numerator:
Accretion of Series E warrant discount	$ 0	$ (94,893)	$ (127,616)	$ (251,893)

Net Loss per Share - Outstandin

Net Loss per Share - Outstanding Options, Warrants and Convertible Preferred Stock Excluded from Computation of Diluted Net Loss per Share (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Convertible Preferred Stock (as converted)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share		2,353,166		2,353,166
Options to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	590,139	542,435	590,139	542,435
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	27,500		27,500
Warrant | Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	170,587	931	170,587	931
Warrant | Convertible Preferred Stock (as converted)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share		51,863		51,863

Warrants - Additional Informati

Warrants - Additional Information (Details) - USD ($)	May. 11, 2015	Jan. 15, 2015	Aug. 22, 2014	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	May. 31, 2015
Class Of Warrant Or Right [Line Items]
Share price					$ 0.13				$ 0.13
Expected risk-free interest rate					1.60%				1.20%
Expected volatility					75.00%				70.00%
Expected term					7 years				4 years 1 month 6 days
Expected dividend yield					0.00%
Fair value of warrants					$ 741,828				$ 741,828
Common stock, at the initial public offering price per shares	$ 14
Preferred stock, shares issued				0	0		0		0
Class of Warrant or Right, Outstanding				0			0
Proceeds from exercise of E warrants							$ 8,948
Fair value of convertible preferred stock warrant liability				$ 0	$ 730,543		0		$ 730,543
Loss on change in fair value of convertible preferred stock warrants				$ 0		$ 0	$ 239,683	$ 56,323
IPO
Class Of Warrant Or Right [Line Items]
Common stock, at the initial public offering price per shares	$ 14
Series E Stock
Class Of Warrant Or Right [Line Items]
Share price			$ 0.31
Warrants exercise price			$ 0.2189
Expected risk-free interest rate			1.60%
Expected volatility			70.00%
Expected term			4 years 6 months
Expected dividend yield			8.00%
Series C-1 Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Warrants exercise price				$ 37.16			$ 37.16
Preferred stock warrants forfeited and cancelled	1,290,350
Class of Warrant or Right, Outstanding					1,290,350				1,290,350
Series C-2 Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Warrants exercise price				$ 24.23			$ 24.23
Class of Warrant or Right, Outstanding					157,912				157,912
Series C-2 Redeemable Convertible Preferred Stock | IPO
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares	1,488
Warrants exercise price	$ 24.23
Class of Warrant or Right, Outstanding				1,488			1,488
Series D Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Warrants exercise price				$ 1.07			$ 1.07
Common stock, at the initial public offering price per shares				$ 14			$ 14
Preferred stock, shares issued				723,050			723,050
Class of Warrant or Right, Outstanding				769,059	769,059		769,059		769,059
Proceeds from exercise of E warrants							$ 1,752
Conversion of stock, shares issued	6,729
Series E Loan Warrants
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares			2,512,562							23,396
Warrants exercise price			$ 0.2189							$ 23.51
Warrants expiration date							Aug. 22, 2024
Warrants exercise price			$ 0.12
Fair value of warrants			$ 301,507		$ 301,507				$ 301,507
Series E Loan Warrants | IPO
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares	23,396
Warrants exercise price	$ 14
Convertible Note Warrants
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares		9,311,586
Warrants exercise price		$ 0.2189		$ 14			$ 14
Warrants expiration date							Jan. 15, 2022
Aggregate consideration		$ 1,354
Convertible Note Warrants | IPO
Class Of Warrant Or Right [Line Items]
Warrants issued to acquire shares	144,772
Warrants exercise price	$ 14
Class of Warrant or Right, Outstanding				144,772			144,772

Warrants -Summary of Outstandin

Warrants -Summary of Outstanding Warrants (Details) - $ / shares	9 Months Ended
	Sep. 30, 2015	May. 11, 2015	Jan. 15, 2015	Dec. 31, 2014
Class Of Warrant Or Right [Line Items]
Number of Warrants	0
Convertible Note Warrants
Class Of Warrant Or Right [Line Items]
Exercise Price/Share	$ 14		$ 0.2189
Expiration Date	2,022
Convertible Note Warrants | IPO
Class Of Warrant Or Right [Line Items]
Number of Warrants	144,772
Exercise Price/Share		$ 14
Common Stock Warrants
Class Of Warrant Or Right [Line Items]
Number of Warrants				931
Exercise Price/Share	$ 6.45
Expiration Date	2,019
Common Stock Warrants | IPO
Class Of Warrant Or Right [Line Items]
Number of Warrants	931
Series C-1 Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Number of Warrants				1,290,350
Exercise Price/Share	$ 37.16
Expiration Date	2,016
Expiration Date	2,017
Series C-2 Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Number of Warrants				157,912
Exercise Price/Share	$ 24.23
Expiration Date	2,015
Series C-2 Redeemable Convertible Preferred Stock | IPO
Class Of Warrant Or Right [Line Items]
Number of Warrants	1,488
Exercise Price/Share		$ 24.23
Series D Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Number of Warrants	769,059			769,059
Exercise Price/Share	$ 1.07
Expiration Date	2,020
Series E Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Number of Warrants				2,512,562
Exercise Price/Share	$ 23.51
Expiration Date	2,024
Series E Redeemable Convertible Preferred Stock | IPO
Class Of Warrant Or Right [Line Items]
Number of Warrants	23,396

Redeemable Convertible Prefer54

Redeemable Convertible Preferred Stock - Additional Information (Details)	May. 11, 2015shares	Apr. 27, 2015	Mar. 31, 2014USD ($)$ / sharesshares	Feb. 04, 2014USD ($)$ / sharesshares	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)$ / sharesshares	Jan. 30, 2015USD ($)shares
Class Of Stock [Line Items]
Common stock, shares authorized				600,000,000	200,000,000		200,000,000		600,000,000
Preferred stock, shares authorized				472,083,383
Common stock, conversion basis		0.0093
Preferred stock par value, per share | $ / shares					$ 0.001		$ 0.001		$ 0.001
Reverse stock split							one-for-107.39
Fair value of warrants | $									$ 741,828
Preferred Stock
Class Of Stock [Line Items]
Fair value of warrants | $					$ 5,665,000		$ 5,665,000
Series E Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Convertible preferred stock, shares authorized				99,132,024
Convertible preferred stock, price per share | $ / shares			$ 0.2189	$ 0.2189	$ 0.2189		$ 0.2189
Preferred stock, shares authorized					0		0		185,046,445
Issuance of preferred stock, net of issuance cost, shares			354,062	34,099,476
Warrants exercise price | $ / shares					$ 23.51		$ 23.51
Common stock, conversion basis	0.009		1
Preferred stock par value, per share | $ / shares					$ 0.001		$ 0.001
Liquidation preference							The Series D Convertible Preferred Stock and Series E Convertible Preferred Stock liquidation preference was equal to two times the original issue price of the Series D Convertible Preferred Stock or Series E Convertible Preferred Stock, respectively, plus any accrued but unpaid dividends whether or not declared.
Outstanding convertible preferred stock	428,237
Preferred stock cumulative dividend percentage							8.00%
Preferred stock redemption value | $					$ 0		$ 0
Stock purchased by convertible note warrant holder, shares										51,681
Stock purchased by convertible note warrant holder for cash consideration | $										$ 7,196
Series A Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Preferred stock, shares authorized					0		0		1,292,084
Common stock, conversion basis	0.030
Preferred stock par value, per share | $ / shares					$ 0.001		$ 0.001
Stock holders voting percentage required for stock redemption							66.67%
Outstanding convertible preferred stock	38,973
Series B Preferred Stock
Class Of Stock [Line Items]
Preferred stock, shares authorized					0		0		11,919,624
Common stock, conversion basis	0.011
Preferred stock par value, per share | $ / shares					$ 0.001		$ 0.001
Outstanding convertible preferred stock	75,835
Series C Preferred Stock
Class Of Stock [Line Items]
Preferred stock par value, per share | $ / shares					0.001		0.001
Series D Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Convertible preferred stock, price per share | $ / shares					$ 0.2189		$ 0.2189
Preferred stock, shares authorized					0		0		237,031,908
Warrants exercise price | $ / shares					$ 1.07		$ 1.07
Common stock, conversion basis	0.009
Preferred stock par value, per share | $ / shares					$ 0.001		$ 0.001
Liquidation preference							The Series D Convertible Preferred Stock and Series E Convertible Preferred Stock liquidation preference was equal to two times the original issue price of the Series D Convertible Preferred Stock or Series E Convertible Preferred Stock, respectively, plus any accrued but unpaid dividends whether or not declared.
Outstanding convertible preferred stock	1,305,984
Preferred stock cumulative dividend percentage							8.00%
Preferred stock cumulative dividends | $							$ 0
Preferred stock redemption value | $					$ 0		$ 0
A B C D Stock And Series E Stock
Class Of Stock [Line Items]
Stock holders voting percentage required for stock redemption							60.00%
Series C-1
Class Of Stock [Line Items]
Common stock, conversion basis	0.014
Outstanding convertible preferred stock	191,406
Series C-2
Class Of Stock [Line Items]
Common stock, conversion basis	0.009
Outstanding convertible preferred stock	93,757
Preferred Shares Excluding Dividends
Class Of Stock [Line Items]
Outstanding convertible preferred stock	2,134,192
Series D And E Preferred Stock Cumulative Dividends
Class Of Stock [Line Items]
Outstanding convertible preferred stock	374,632
Preferred stock cumulative dividends | $									$ 7,643,378
Series E Warrants
Class Of Stock [Line Items]
Purchase of warrant exercise price per share | $ / shares				$ 0.001
Purchase price of preferred stock per Series E warrant | $ / shares			$ 0.0001	0.0001
Warrants exercise price | $ / shares			$ 0.001	$ 0.001
Financial institution warrant issued, share			118,017	11,366,486
Proceeds from Issuance of preferred stock and warrants | $			$ 77,634	$ 7,476,879
Fair value of warrants | $					1,890,000		$ 1,890,000
Accretion of Series E warrant discount | $					$ 0	$ 94,893	127,616	$ 251,893
Warrant Issuance Costs | $							$ 48,384
Preferred stock accreted redemption period							5 years
Series E Warrants | Maximum
Class Of Stock [Line Items]
Financial institution warrant issued, share				33,044,008
Series E Warrants | Series E Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Convertible preferred stock, price per share | $ / shares					$ 0.1645		$ 0.1645
Tranche One | Series E Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Financial institution warrant issued, share				49,566,012
Tranche One | Series E Warrants
Class Of Stock [Line Items]
Financial institution warrant issued, share				16,522,004

Redeemable Convertible Prefer55

Redeemable Convertible Preferred Stock - Schedule of Preferred Stock (Details) - USD ($)	May. 11, 2015	Sep. 30, 2015
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering		$ 57,356,049
Carrying value including cumulative dividends	$ 57,356,049
Preferred shares before IPO including cumulative dividends	217,515,139
Common shares after IPO including dividends	2,508,824
Series A Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering	$ 1,403,007	$ (1,403,007)
Preferred Shares Before IPO	1,292,084	(1,292,084)
Common Shares After IPO	38,973
Series B Preferred Stock
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering	$ 2,100,149	$ (2,100,149)
Preferred Shares Before IPO	6,789,712	(6,789,712)
Common Shares After IPO	75,835
Series C-1
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering	$ 4,569,063
Preferred Shares Before IPO	13,242,612
Common Shares After IPO	191,406
Series C-2
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering	$ 2,225,619
Preferred Shares Before IPO	9,948,331
Common Shares After IPO	93,757
Series D Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering	$ 30,370,273	$ (38,163,280)
Preferred Shares Before IPO	140,252,678	(140,252,678)
Common Shares After IPO	1,305,984
Series E Preferred Stock
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering	$ 7,879,873	$ (8,894,931)
Preferred Shares Before IPO	45,989,722	(45,989,722)
Common Shares After IPO	428,237
Preferred Shares Excluding Dividends
Class Of Stock [Line Items]
Conversion of preferred stock into common stock at initial public offering	$ 48,547,984
Preferred Shares Before IPO	217,515,139
Common Shares After IPO	2,134,192
Series D And E Preferred Stock Cumulative Dividends
Class Of Stock [Line Items]
Common Shares After IPO	374,632
Cumulative Dividends	$ 8,808,065

Stockholders Equity (Deficit) -

Stockholders Equity (Deficit) - Additional Information (Details) - USD ($)	1 Months Ended						9 Months Ended
	Jun. 30, 2015	May. 31, 2015	May. 31, 2014	Mar. 31, 2014	Feb. 28, 2014	Jan. 31, 2014	Sep. 30, 2015	Sep. 30, 2014	May. 11, 2015	Dec. 31, 2014	Feb. 04, 2014
Class Of Stock [Line Items]
Amendment date of entity incorporation							May 11, 2015
Common stock, shares authorized							200,000,000			600,000,000	600,000,000
Common stock, par value							$ 0.001			$ 0.001
Common stock, shares issued							6,841,260			334,003
Common stock, voting rights							Each share of common stock is entitled to one vote. All shares of common stock rank equally as to voting and all other matters that the holders are entitled to vote on.
Common stock, conversion features							The shares of common stock have no preemptive or conversion rights, no redemption or sinking fund provisions, no liability for further call or assessment, and are not entitled to cumulative voting rights
Preferred stock, shares authorized							10,000,000			0
Preferred stock, par value							$ 0.001			$ 0.001
Vesting period of options							2 years 6 months
Options to purchase common stock outstanding							590,139
Options fully vested							371,563
Unrecognized compensation expense							$ 583,701
Compensation expense period expected to be recognized							2 years 6 months
2014 Equity Incentive Plan
Class Of Stock [Line Items]
Shares reserved for issuance									940,112
Number of shares available for issuance							923,031
Stock-based Compensation | 2011 Equity Incentive Plan
Class Of Stock [Line Items]
Percentage of increase on outstanding shares					20.00%
Number of Shares, Granted					0
Employee Stock Option | 2011 Equity Incentive Plan
Class Of Stock [Line Items]
Number of Shares, Granted			8,685	249,361		2,094		260,140
Shares reserved for issuance									14,006
Share based compensation arrangement by share based payment award, options, grants in period, weighted average grant date fair value			$ 2.15	$ 2.15		$ 2.15
Employee Stock Option | 2014 Equity Incentive Plan
Class Of Stock [Line Items]
Number of Shares, Granted	12,083	5,000					17,083
Options to purchase common stock outstanding							590,139			595,577
Share based compensation arrangement by share based payment award, options, grants in period, weighted average grant date fair value	$ 13.83	$ 14.64
Restricted Stock Units R S U
Class Of Stock [Line Items]
Unrecognized compensation expense							$ 149,875
Compensation expense period expected to be recognized							6 months
Share based compensation arrangement by share based payment award, options, grants in period, weighted average grant date fair value							$ 5.45
Restricted stock vesting right description							RSUs vest 100% on March 31, 2016.
Stock issued during period, shares, share based compensation, gross							27,500
Restricted Stock Units R S U | RSUs Vest
Class Of Stock [Line Items]
Share based compensation arrangement by share based payment award, award vesting rights, percentage							100.00%

Stockholders Equity (Deficit)57

Stockholders Equity (Deficit) - Summary of Stock Option Plans Activity (Details) - USD ($)	1 Months Ended		9 Months Ended	12 Months Ended
	Jun. 30, 2015	May. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Ending Balance			590,139
Employee Stock Option | 2014 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Beginning Balance			595,577
Number of Shares, Granted	12,083	5,000	17,083
Number of Shares, Exercised			(13,764)
Number of Shares, Forfeited			(8,757)
Number of Shares, Ending Balance			590,139	595,577
Number of Shares, Vested and expected to vest			580,001
Number of Shares, Exercisable			371,573
Weighted-Average Exercise Price Per Share, Beginning Balance			$ 3.71
Weighted-Average Exercise Price Per Share, Granted	$ 13.83	$ 14.64
Weighted-Average Exercise Price Per Share, Exercised			2.47
Weighted-Average Exercise Price Per Share, Forfeited			5.42
Weighted-Average Exercise Price Per Share, Ending Balance			4.01	$ 3.71
Weighted-Average Exercise Price Per Share, Vested and expected to vest			4.01
Weighted-Average Exercise Price Per Share, Exercisable			$ 3.45
Weighted-Average Remaining Contractual Life, Outstanding			7 years 1 month 6 days	7 years 9 months 18 days
Weighted-Average Remaining Contractual Life, Vested and expected to vest			7 years 1 month 6 days
Weighted-Average Remaining Contractual Life, Exercisable			6 years 3 months 18 days
Exercised			$ 92,582
Aggregate Intrinsic Value, Ending Balance			5,258,488
Aggregate Intrinsic Value, Vested and expected to vest			5,203,992
Aggregate Intrinsic Value, Exercisable			$ 3,508,953

Stockholders Equity (Deficit)58

Stockholders Equity (Deficit) - Summary of Stock Option Grant Activity and Related Fair Value Information (Details) - Employee Stock Option - $ / shares	1 Months Ended					9 Months Ended
	Jun. 30, 2015	May. 31, 2015	May. 31, 2014	Mar. 31, 2014	Jan. 31, 2014	Sep. 30, 2015	Sep. 30, 2014
2014 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Granted	12,083	5,000				17,083
Exercise Price	$ 13.83	$ 14.64
Fair Value of Common Stock on Date of Grant	$ 13.83	$ 14.64
2011 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Granted			8,685	249,361	2,094		260,140
Exercise Price			$ 2.15	$ 2.15	$ 2.15
Fair Value of Common Stock on Date of Grant			$ 2.15	$ 2.15	$ 2.15

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended	9 Months Ended
	Oct. 31, 2012	Jun. 30, 2012	Sep. 30, 2015	Sep. 30, 2015
Commitments And Contingencies [Line Items]
Percentage of requisite preferred holders who approved plan to set aside proceeds of any sale of to be distributed	60.00%
Lease expiration term				The Company leases office and laboratory space under two non-cancelable operating leases in Tucson, Arizona, which were set to expire in November and December 2015, respectively, as of September 30, 2015. Under the terms of the two Tucson leases, the Company had one option to extend the leases for five years at the end of the initial seven year lease term.
Lease extension term, in years				5 years
Expected increase in lease rent				$ 804,000
Additional cash outlay commitment expense			$ 500,000
Merck Sharp And Dohme Corporation [Member]
Commitments And Contingencies [Line Items]
Non-exclusive license agreement, milestone accrued or paid		$ 0
Tucson
Commitments And Contingencies [Line Items]
Lease extension term, in years				5 years
Lease term				7 years
Minimum
Commitments And Contingencies [Line Items]
Percentage of proceeds of any sale to be distributed to employees, directors, or consultants	15.00%
Minimum | Merck Sharp And Dohme Corporation [Member]
Commitments And Contingencies [Line Items]
Non-exclusive license agreement, contingent milestone payments		$ 50,000
Non-exclusive license agreement, future royalties		3.00%
Maximum | Merck Sharp And Dohme Corporation [Member]
Commitments And Contingencies [Line Items]
Non-exclusive license agreement, contingent milestone payments		$ 1,000,000
Non-exclusive license agreement, future royalties		6.00%

Commitments and Contingencies60

Commitments and Contingencies - Minimum Lease Payments Before Common Area Maintenance Charges (Details)	Sep. 30, 2015USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,016	$ 507,948
2,017	510,323
2,018	512,734
2,019	515,181
2,020	$ 517,664

Commitments and Contingencies61

Commitments and Contingencies - Schedule Of Product Warranty Liability (Details)	3 Months Ended
	Sep. 30, 2015USD ($)
Commitments And Contingencies Disclosure [Abstract]
Warranty reserve, beginning balance	$ 0
Cost of warranty claims	(545)
Warranty accrual	17,225
Warranty reserve, ending balance	$ 16,680

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income tax examination, likelihood of unfavorable settlement			Greater than 50 percent
Accrued interest or penalties	$ 0		$ 0		$ 0
Recognized interest or penalties	$ 0	$ 0	$ 0	$ 0

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2015USD ($)Agreement	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)Agreement	Sep. 30, 2014USD ($)
Related Party Transaction [Line Items]
Number of consulting agreement | Agreement	2		2
Series D Stock Holder
Related Party Transaction [Line Items]
Consulting fees paid to stockholder	$ 0	$ 77,550	$ 0	$ 99,800
Series E Stock Holder
Related Party Transaction [Line Items]
Consulting fees paid to stockholder	$ 0	$ 77,550	$ 0	$ 99,800

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Illumina, Inc. Agreement - USD ($)	Oct. 29, 2015	Sep. 30, 2015
Subsequent Event [Line Items]
Milestone completion date		Oct. 29, 2015
Subsequent Event
Subsequent Event [Line Items]
Non-refundable initial fee	$ 100,000